Hims & Hers Health (HIMS) 10-K 26 Feb 24 2023 FY Annual report Financial data

Cover

Cover - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2023	Feb. 23, 2024	Jun. 30, 2023
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity Registrant Name	HIMS & HERS HEALTH, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38986
Entity Tax Identification Number	98-1482650
Entity Address, Address Line One	2269 Chestnut Street, #523
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94123
City Area Code	415
Local Phone Number	851-0195
Title of 12(b) Security	Class A common stock, $0.0001 par value per share
Trading Symbol	HIMS
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 1.8
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement to be delivered to stockholders in connection with the 2024 annual meeting of stockholders are incorporated by reference in response to Part III of this Annual Report on Form 10-K to the extent stated herein. The 2024 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Central Index Key	0001773751
Common Class A
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		205,872,690
Common Class V
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		8,377,623

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2023
Audit Information [Abstract]
Auditor Name	KPMG LLP
Auditor Firm ID	185
Auditor Location	San Francisco, CA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 96,663	$ 46,772
Short-term investments	124,318	132,853
Inventory	22,464	21,562
Prepaid expenses and other current assets	21,608	15,408
Total current assets	265,053	216,595
Restricted cash	856	856
Goodwill	110,881	110,881
Property, equipment, and software, net	36,143	11,199
Intangible assets, net	18,574	21,841
Operating lease right-of-use assets	9,588	4,936
Other long-term assets	91	33
Total assets	441,186	366,341
Current liabilities:
Accounts payable	43,070	32,363
Accrued liabilities	28,972	12,448
Deferred revenue	7,733	1,472
Earn-out payable	7,412	0
Operating lease liabilities	1,281	1,658
Total current liabilities	88,468	47,941
Operating lease liabilities	8,667	3,649
Earn-out liabilities	0	2,975
Other long-term liabilities	22	35
Total liabilities	97,157	54,600
Commitments and contingencies (Note 14)
Stockholders' equity:
Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 205,104,120 and 200,051,689 shares issued and outstanding as of December 31, 2023 and 2022, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of December 31, 2023 and 2022	21	21
Additional paid-in capital	712,307	656,626
Accumulated other comprehensive loss	(124)	(277)
Accumulated deficit	(368,175)	(344,629)
Total stockholders' equity	344,029	311,741
Total liabilities and stockholders' equity	$ 441,186	$ 366,341

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Common Class A
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	2,750,000,000	2,750,000,000
Common stock, shares issued (in shares)	205,104,120	200,051,689
Common stock, shares outstanding (in shares)	205,104,120	200,051,689
Common Class V
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, shares issued (in shares)	8,377,623	8,377,623
Common stock, shares outstanding (in shares)	8,377,623	8,377,623

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 872,000	$ 526,916	$ 271,878
Cost of revenue	157,051	118,194	67,384
Gross profit	714,949	408,722	204,494
Operating expenses:
Marketing	446,435	272,587	135,902
Operations and support	119,857	77,403	47,593
Technology and development	48,227	29,237	22,379
General and administrative	129,883	98,192	113,662
Total operating expenses	744,402	477,419	319,536
Loss from operations	(29,453)	(68,697)	(115,042)
Other income (expense):
Change in fair value of liabilities	(1,075)	70	3,802
Other income, net	8,957	2,918	445
Total other income, net	7,882	2,988	4,247
Loss before income taxes	(21,571)	(65,709)	(110,795)
(Provision) benefit for income taxes	(1,975)	31	3,136
Net loss	(23,546)	(65,678)	(107,659)
Other comprehensive income (loss)	153	(140)	(126)
Total comprehensive loss	$ (23,393)	$ (65,818)	$ (107,785)
Net loss per share attributable to common stockholders:
Basic (in USD per share)	$ (0.11)	$ (0.32)	$ (0.58)
Diluted (in USD per share)	$ (0.11)	$ (0.32)	$ (0.58)
Weighted average shares outstanding:
Basic (in shares)	209,344,712	204,516,120	186,781,537
Diluted (in shares)	209,344,712	204,516,120	186,781,537

Consolidated Statements of Mezz

Consolidated Statements of Mezzanine Equity and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Redeemable Convertible Preferred Stock
Mezzanine equity, beginning balance (in shares) at Dec. 31, 2020						93,328,118
Mezzanine equity, beginning balance at Dec. 31, 2020						$ 249,962
Increase (Decrease) in Temporary Equity [Roll Forward]
Pre-closing stock repurchase, net of exercise of vested options (in shares)						(206,511)
Pre-closing stock repurchase, net of exercise of vested options						$ (125)
Conversion of convertible securities (in shares)						(93,121,607)
Conversion of convertible securities						$ (249,837)
Mezzanine equity, ending balance (in shares) at Dec. 31, 2021						0
Mezzanine equity, ending balance at Dec. 31, 2021						$ 0
Beginning balance (in shares) at Dec. 31, 2020		52,967,106
Beginning balance at Dec. 31, 2020	$ (146,874)	$ 5	$ 24,424	$ (11)	$ (171,292)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock repurchased during period (in shares)		(1,817,519)
Stock repurchased during period	(21,902)		(21,902)
Conversion of redeemable convertible preferred stock to common stock (in shares)		93,121,607
Conversion of redeemable convertible preferred stock to common stock	249,837	$ 9	249,828
Repayment of related-party promissory notes associated with vested shares	854		854
Forfeiture of related-party promissory notes (in shares)		(370,734)
Conversion of Series D preferred stock warrants to Class A common warrants	1,160		1,160
Exercise of Class A common stock warrants (in shares)		1,867,380
Exercise of Class A common stock warrants	21,679		21,679
Issuance of common stock upon Merger, net of transaction costs (in shares)		24,142,244
Issuance of common stock upon Merger, net of transaction costs	129,659	$ 2	129,657
Issuance of PIPE shares (in shares)		7,500,000
Issuance of PIPE shares	75,000	$ 1	74,999
Warrant expense in connection with Merger	154		154
Issuance of Merger earn-out shares to common stockholders (in shares)		14,153,520
Issuance of Merger earn-out shares to common stockholders	1	$ 1
Issuance of common stock for acquisition of businesses (in shares)		8,699,815
Issuance of common stock for acquisition of businesses	52,614	$ 1	52,613
Exercise of vested stock options (in shares)		1,382,978
Exercise of vested stock options	1,259	$ 1	1,258
Vesting of early exercised stock options (in shares)		(2,812)
Vesting of early exercised stock options, net of cancelations	227		227
Stock-based compensation	67,767		67,767
Issuance of common stock upon vesting of RSUs, net of shares withheld for taxes (in shares)		1,189,786
Payments for taxes related to net share settlement of equity awards	(5,998)		(5,998)
Issuance of common stock upon Class A common stock warrant redemption (in shares)		1,958,615
Issuance of common stock upon Class A common stock warrant redemption	16,967		16,967
Other comprehensive income (loss)	(126)			(126)
Net loss	(107,659)				(107,659)
Ending balance (in shares) at Dec. 31, 2021		204,791,986
Ending balance at Dec. 31, 2021	334,619	$ 20	613,687	(137)	(278,951)
Mezzanine equity, ending balance (in shares) at Dec. 31, 2022						0
Mezzanine equity, ending balance at Dec. 31, 2022						$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of vested stock options (in shares)		1,611,687
Exercise of vested stock options	2,246	$ 1	2,245
Vesting of early exercised stock options, net of cancelations	197		197
Stock-based compensation	43,220		43,220
Issuance of common stock upon vesting of RSUs, net of shares withheld for taxes (in shares)		1,632,111
Payments for taxes related to net share settlement of equity awards	(3,901)		(3,901)
Stock issued during period, shares, employee stock purchase plans (in shares)		393,528
Stock Issued During Period, Value, Employee Stock Purchase Plan	1,178		1,178
Other comprehensive income (loss)	(140)			(140)
Net loss	(65,678)				(65,678)
Ending balance (in shares) at Dec. 31, 2022		208,429,312
Ending balance at Dec. 31, 2022	311,741	$ 21	656,626	(277)	(344,629)
Mezzanine equity, ending balance (in shares) at Dec. 31, 2023						0
Mezzanine equity, ending balance at Dec. 31, 2023						$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of vested stock options (in shares)		1,222,548
Exercise of vested stock options	2,322		2,322
Stock-based compensation	67,156		67,156
Issuance of common stock upon vesting of RSUs, net of shares withheld for taxes (in shares)		3,472,456
Payments for taxes related to net share settlement of equity awards	(14,096)		(14,096)
Stock issued during period, shares, employee stock purchase plans (in shares)		594,885
Stock Issued During Period, Value, Employee Stock Purchase Plan	2,298		2,298
Stock repurchased and retired during period (in shares)		237,458
Repurchases and retirement of common stock	1,999		1,999
Other comprehensive income (loss)	153			153
Net loss	(23,546)				(23,546)
Ending balance (in shares) at Dec. 31, 2023		213,481,743
Ending balance at Dec. 31, 2023	$ 344,029	$ 21	$ 712,307	$ (124)	$ (368,175)

Consolidated Statements of Me_2

Consolidated Statements of Mezzanine Equity and Stockholders' Equity (Deficit) (Parenthetical) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Statement of Stockholders' Equity [Abstract]
Common stock issuance costs	$ 18.7

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating activities
Net loss	$ (23,546,000)	$ (65,678,000)	$ (107,659,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	9,515,000	7,474,000	4,075,000
Stock-based compensation	66,080,000	42,817,000	67,211,000
Change in fair value of liabilities	1,075,000	(70,000)	(3,802,000)
Warrant expense in connection with Merger	0	0	154,000
Amortization of debt issuance costs	0	0	144,000
Net (accretion) amortization on securities	(5,686,000)	146,000	2,166,000
Benefit for deferred taxes	(13,000)	(594,000)	(3,388,000)
Impairment of long-lived assets	429,000	1,127,000	0
Non-cash operating lease cost	1,922,000	1,605,000	1,510,000
Non-cash acquisition-related costs	2,691,000	837,000	1,182,000
Non-cash other	195,000	0	540,000
Changes in operating assets and liabilities:
Inventory	(902,000)	(8,004,000)	(9,628,000)
Prepaid expenses and other current assets	(6,395,000)	(6,335,000)	3,200,000
Other long-term assets	(58,000)	17,000	(58,000)
Accounts payable	7,324,000	12,723,000	9,853,000
Accrued liabilities	16,524,000	909,000	197,000
Deferred revenue	6,261,000	(1,716,000)	1,412,000
Operating lease liabilities	(1,933,000)	(1,605,000)	(1,521,000)
Earn-out payable	0	(10,184,000)	0
Net cash provided by (used in) operating activities	73,483,000	(26,531,000)	(34,412,000)
Investing activities
Purchases of investments	(157,239,000)	(187,700,000)	(266,633,000)
Maturities of investments	170,051,000	194,259,000	158,375,000
Proceeds from sales of investments	1,574,000	35,846,000	3,465,000
Investment in website and mobile application development and internal-use software	(9,272,000)	(4,533,000)	(4,175,000)
Purchases of property, equipment, and intangible assets	(17,220,000)	(2,714,000)	(832,000)
Deferred consideration paid for acquisitions	0	(459,000)	0
Acquisition of businesses, net of cash acquired	0	0	(46,468,000)
Net cash (used in) provided by investing activities	(12,106,000)	34,699,000	(156,268,000)
Financing activities
Pre-closing stock repurchase	0	0	(22,027,000)
Proceeds from issuance of common stock upon Merger	0	0	197,686,000
Proceeds from PIPE	0	0	75,000,000
Payments for transaction costs related to securities issuances	0	0	(12,851,000)
Proceeds from repayment of promissory notes associated with vested and unvested shares	0	0	1,193,000
Proceeds from exercise of Class A common stock warrants, net of redemption payments	0	0	787,000
Proceeds from exercise of vested and unvested stock options, net of repurchases and cancelations	2,322,000	2,246,000	1,253,000
Payments for taxes related to net share settlement of equity awards	(14,096,000)	(3,901,000)	(5,998,000)
Payments for earn-out consideration for acquisitions	0	(32,650,000)	0
Proceeds from employee stock purchase plan	2,298,000	1,178,000	0
Repurchases of common stock	(1,999,000)	0	0
Net cash (used in) provided by financing activities	(11,475,000)	(33,127,000)	235,043,000
Foreign currency effect on cash and cash equivalents	(11,000)	(53,000)	(73,000)
Increase (decrease) in cash, cash equivalents, and restricted cash	49,891,000	(25,012,000)	44,290,000
Cash, cash equivalents, and restricted cash at beginning of period	47,628,000	72,640,000	28,350,000
Cash, cash equivalents, and restricted cash at end of period	97,519,000	47,628,000	72,640,000
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents	96,663,000	46,772,000	71,784,000
Restricted cash	856,000	856,000	856,000
Total cash, cash equivalents, and restricted cash	97,519,000	47,628,000	72,640,000
Supplemental disclosures of cash flow information
Cash paid for taxes	1,109,000	636,000	338,000
Non-cash investing and financing activities
Recapitalization of redeemable convertible preferred stock from pre-closing stock repurchase	0	0	125,000
Conversion of redeemable convertible preferred stock to common stock	0	0	249,837,000
Assumption of Merger warrants liability	0	0	51,814,000
Redemption/exercise of Class A common stock warrants	0	0	37,834,000
Conversion of Series D preferred stock warrants to Class A common warrants	0	0	1,160,000
Purchase of property and equipment included in accounts payable	3,383,000	0	0
Right-of-use asset obtained in exchange for lease liability	6,270,000	1,206,000	0
Vesting of early exercised stock options, net of cancelations	0	197,000	227,000
Common stock issued, contingent consideration, and liabilities assumed in acquisition of businesses	$ 0	$ 0	$ 99,958,000

Organization

Organization	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Hims & Hers Health, Inc. (the “Company” or “Hims & Hers”), incorporated in Delaware, is a consumer-first platform transforming the way customers fulfill their health and wellness needs. The Company’s mission is to help the world feel great through the power of better health. The Hims & Hers platform includes access to a highly-qualified and technologically-capable provider network, a clinically-focused electronic medical records system, digital prescriptions, and cloud-enabled pharmacy fulfillment. The Company’s digital platform enables access to treatments for a broad range of conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate. Prescriptions are fulfilled online through licensed pharmacies on a subscription basis, making accessing treatments simple, affordable, and straightforward. Through the Hims & Hers mobile applications, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness. In addition, the Company offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. The Company’s products and services are available for purchase directly by customers on the Company’s websites and mobile applications. Additionally, Hims & Hers non-prescription products can be found in tens of thousands of top retail locations in the United States. On January 20, 2021 (the “Closing Date”), OAC completed the acquisition of Hims, Inc. (“Hims”) pursuant to the Agreement and Plan of Merger dated as of September 30, 2020 (the “Merger Agreement”) by and among OAC, Hims, and Rx Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of OAC (“Merger Sub”). The Merger Agreement provided for, among other things, the combination of Hims and OAC pursuant to the merger of Merger Sub with and into Hims, with Hims continuing as the surviving entity and as a wholly-owned subsidiary of OAC, which changed its name to Hims & Hers Health, Inc. (the “Merger”). The Merger was accounted for as a reverse recapitalization with Hims as the accounting acquirer and OAC as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the consolidated financial statements represents the accounts of Hims and its wholly-owned subsidiaries as if Hims is the predecessor to the Company. The share and per share information in these consolidated financial statements has therefore been retroactively restated to reflect the share exchange ratio established in the Merger (0.4530 shares of Company Class A common stock for 1 share of Hims Class A common stock). Prior to the Merger, OAC ordinary shares and warrants were traded on the New York Stock Exchange (“NYSE”) under the ticker symbols “OAC” and “OAC WS”, respectively. On the Closing Date, the Company’s Class A common stock and warrants began trading on the NYSE under the ticker symbols “HIMS” and “HIMS WS”, respectively. Upon the completion of the warrant redemption in August 2021, the Company is trading on the NYSE solely under the ticker symbol “HIMS”. One of the primary purposes of the Merger was to provide a platform for Hims to gain access to the U.S. capital markets. See Note 3 – Recapitalization for additional details.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities for which it is the primary beneficiary. All intercompany transactions and balances have been eliminated in the consolidated financial statements herein. For the years ended December 31, 2023, 2022, and 2021, the Company had operations primarily in the United States, with insignificant operations in the United Kingdom. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and accompanying notes. The more significant estimates, judgments, and assumptions by management include, among others, valuation of inventory, valuation and recognition of stock-based compensation expense, valuation of contingent consideration in business combinations, purchase price allocation for business combinations, estimates used in the capitalization of website and mobile application development and internal-use software costs, and judgments relating to impairment triggering events for long-lived assets. Management believes that the estimates, judgments, and assumptions upon which it relies are reasonable based upon information available to it at the time that these estimates, judgments, and assumptions were made. Actual results experienced by the Company may differ from management’s estimates. To the extent that there are material differences between these estimates and actual results, the Company’s consolidated financial statements will be affected. Risks and Uncertainties The Company’s business, operations, and financial results are subject to various risks and uncertainties, including adverse United States economic conditions, legal restrictions, changing laws for medical services and prescription products, decisions to outsource or modify portions of its supply chain, and competition in its industry, and of which could adversely affect its business, financial condition, results of operations, and cash flows. These significant factors, among others, could cause the Company’s future results to differ materially from the consolidated financial statements. Concentration Risk The Company’s financial instruments that are potentially exposed to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, investments, and accounts receivable. The Company maintains its cash, cash equivalents, short-term investments, and restricted cash with high-quality financial institutions with investment-grade ratings. The majority of the cash balances are with U.S. banks and are insured to the extent defined by the Federal Deposit Insurance Corporation. The prescription products ordered on the Company’s e-commerce online platform are primarily fulfilled by the Affiliated and Partner Pharmacies (as defined below). If any of the pharmacies were to stop fulfilling orders, it could significantly slow prescription product sales until fulfillment volume is redistributed to other operating pharmacies. The Company maintains agreements with these pharmacies and is continuing to invest in expanding affiliated pharmacy fulfillment capabilities to mitigate any such risk. As of December 31, 2023, four wholesale customers individually represented more than 10% of accounts receivable. As of December 31, 2022, two wholesale customers represented more than 10% of accounts receivable. For the years ended December 31, 2023, 2022, and 2021, no single customer represented more than 10% of revenue. In addition, revenue related to sales in foreign countries was less than 10% of revenue for each of those years. Foreign Currency Translation The Company’s consolidated financial statements are presented in U.S. dollars. Adjustments resulting from translating foreign functional currency financial statements into U.S. dollars are presented as foreign currency translation adjustments, a component of other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. Business Combinations The Company accounts for its business combinations using the acquisition method of accounting. The purchase price is attributed to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company’s consolidated financial statements from the date of acquisition. When the Company issues stock-based or cash awards to an acquired company’s shareholders, the Company evaluates whether the awards are consideration or compensation for post-acquisition services. The evaluation includes, among other things, whether the vesting of the awards is contingent on the continued employment of the acquired company’s stockholders beyond the acquisition date. If continued employment is required for vesting, the awards are treated as compensation for post-acquisition services and recognized as expense over the requisite service period. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain assumed obligations. Any acquired assets from a business combination including intangible assets subject to amortization are continuously monitored and reviewed for potential impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In such cases, recoverability of assets to be held and used is assessed by comparing the carrying amount of assets with their future underlying net undiscounted cash flows without interest charges. If such assets are considered to be impaired, an impairment is recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets. Segment Reporting The Company is managed as a single operating segment on a consolidated basis, inclusive of acquisitions. The Company determined that the Chief Executive Officer (“CEO”) is the chief operating decision maker as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions and managing the organization at a consolidated level. Cash, Cash Equivalents, and Restricted Cash The Company considers all highly liquid investments purchased with an original maturity or remaining maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash and cash equivalents with financial institutions. The restricted cash balance comprises cash collateral that is held by the Company’s primary financial institution to secure a letter of credit issued as a security deposit for the Company’s warehouse facility in New Albany, Ohio. Investments Available-for-sale debt instruments with original maturities at the date of purchase greater than three months and remaining maturities of less than one year are classified as short-term investments. Available-for-sale debt instruments with original maturities at the date of purchase and remaining maturities of greater than one year are classified as long-term investments. The Company intends to sell such investments, if any, at or close to maturity. The investments are designated as available-for-sale and are reported at fair value, with unrealized gains and losses, net of tax, recorded in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss, except for other-than-temporary impairments and credit losses. The Company determines the cost of the investment sold based on specific identification at the individual security level. The Company records the interest income and realized gains and losses on the sale of these instruments within other income (expense), net on the consolidated statements of operations and comprehensive loss. Other-Than-Temporary Impairment and Credit Losses The Company adopted ASC Topic 326 for the year ended December 31, 2021, and considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company’s available-for-sale securities for the years ended December 31, 2023, 2022, or 2021 were caused by fluctuations in market value and interest rates as a result of the economic environment. The Company concluded that an allowance for credit losses for its available-for-sale securities was unnecessary as of December 31, 2023 and 2022 because the decline in the market value was attributable to changes in market conditions and not credit quality, and that it is neither management’s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. There was no realized gain or loss on available-for-sale securities in the periods presented. Fair Value of Financial Instruments The fair value of a financial instrument is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities subject to ongoing fair value measurement are categorized and disclosed into one of the three categories depending on observable or unobservable inputs employed in the measurement. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. • Level 2: Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. • Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Inventory Inventory primarily consists of finished goods and raw materials that are located at Company-managed and third-party fulfillment warehouses and pharmacies. Inventory is stated at the lower of cost and net realizable value and inventory cost is determined by the weighted average cost method. The Company reserves for expired, slow-moving, and excess inventory by estimating the net realizable value based on the potential future use of such inventory. Management monitors inventory to identify events that would require impairment due to slow-moving, expired, or obsolete inventory and reduces the value of inventory when required. Obsolete inventory balances are written off against the inventory allowance when management determines that the inventory cannot be sold. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of balances related to prepayments or vendor deposits for insurance, marketing, software, inventory and other operating costs, and trade and other accounts receivables. Prepaid expenses are recorded when payment has been made in advance for goods and services. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Receivables are stated at amounts estimated by management to be equal to their net realizable values. The allowance for doubtful accounts is the Company's best estimate of the amount of expected credit losses on its accounts receivable. The expectation of collectability is based on the Company's review of credit profiles of customers, contractual terms and conditions, current economic trends, and historical payment experience. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and an allowance is recorded accordingly. Account balances are written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of December 31, 2023 and 2022, gross accounts receivable was $6.7 million and $3.9 million, respectively. There were immaterial write-offs of accounts receivable for the year ended December 31, 2023 and no write-offs of accounts receivable for the years ended December 31, 2022 or 2021. As of December 31, 2023 and 2022, the Company had no allowances for doubtful accounts. The Company does not have any off-balance sheet credit exposure related to its customers. Property, Equipment, and Software, Net Property, equipment, and software consist of purchased and internal-use software and website development, facility equipment and other tangible property, leasehold improvements, and assets not placed in service. Property, equipment, and software are depreciated or amortized using the straight-line method over the estimated useful lives ranging from two Capitalizable website and mobile application development and internal-use software costs are recorded at cost, less amortization. The costs incurred during the website application and infrastructure stages as well as costs incurred during the graphics and content development stages are capitalized; all other costs are expensed as incurred. In addition, the Company incurs costs to develop software for internal use. The costs incurred during the application development phase are capitalized until the project is completed and the asset is ready for intended use. All costs that relate to the preliminary project and post-implementation operation phases of development are expensed as incurred. The following table summarizes the estimated amortization of website development and internal-use software costs subsequent to December 31, 2023 (in thousands): 2024 $ 6,461 2025 5,058 2026 2,568 Total $ 14,087 Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized but is tested for impairment annually in the fourth quarter or more frequently if events or changes in circumstances indicate that the asset may be impaired. The Company operates as one reporting unit. When testing goodwill for impairment, the Company may first perform an optional qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company will recognize an impairment loss in an amount equal to that excess but limited to the total amount of goodwill. Goodwill of $110.9 million was acquired during 2021 and no goodwill impairment was recorded for the years ended December 31, 2023, 2022, and 2021. Intangible Assets, Net Intangible assets, net primarily includes trade name, customer relationships, and developed technology. The Company amortizes such definite-lived intangible assets on a straight-line basis over the assets’ estimated useful lives of one Impairment of Long-Lived Assets Long-lived assets include property and equipment, website and mobile application development and internal-use software, and intangible assets subject to amortization. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In such cases, recoverability of assets to be held and used is assessed by comparing the carrying amount of assets with their future underlying net undiscounted cash flows without interest charges. If such assets are considered to be impaired, an impairment is recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets. The Company recognized $0.4 million and $1.1 million of impairment charges on long-lived assets during the years ended December 31, 2023 and 2022 in general and administrative expenses on the consolidated statements of operations and comprehensive loss. There were no impairment charges on long-lived assets during the year ended December 31, 2021. Operating Leases The Company determines if an arrangement contains a lease at inception based on whether there is identified property, plant, or equipment and whether the Company controls the use of the identified asset throughout the period of use. The Company leases facilities for fulfillment and corporate purposes under non-cancelable operating leases with expiration dates between fiscal years 2025 and 2027. The Company's operating leases are reflected in the operating lease right-of-use (“ROU”) assets and in the operating lease liabilities in the accompanying consolidated balance sheets. The operating lease ROU assets represent the Company’s right to use the underlying assets for the lease terms and the lease liabilities represent the Company’s obligation to make lease payments arising from the leases. The operating lease ROU assets and lease liabilities are recognized at each lease’s inception date based on the present value of lease payments over the lease term discounted based on the more readily determinable of (i) the rate implicit in the lease or (ii) the Company’s incremental borrowing rate, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease. Because the Company’s operating leases do not provide an implicit rate, the Company estimates its incremental borrowing rate at the lease commencement date for borrowings with a similar term. The Company’s operating lease ROU assets are measured based on the corresponding operating lease liability adjusted for (i) payments made to the lessor at or before the commencement date, (ii) initial direct costs incurred, and (iii) tenant incentives under the lease. The Company does not assume renewals or early terminations unless it is reasonably certain to exercise these options at commencement. The Company monitors for events or changes in circumstances that require a reassessment of its leases. When a reassessment results in the remeasurement of a lease liability, an adjustment is made to the carrying amount of the corresponding ROU asset. The Company does not allocate consideration between lease and non-lease components. The Company's lease agreements contain variable costs such as common area maintenance, operating expenses, or other costs. Variable lease payments are recognized in the period in which the obligation for those payments are incurred. In addition, the Company does not recognize ROU assets or operating lease liabilities for leases with a term of 12 months or less of all asset classes. Operating lease expense is recognized on a straight-line basis over each lease term. Revenue Recognition The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. The Company’s consolidated revenue primarily comprises online sales of health and wellness products and services through the Company’s websites and mobile applications, including prescription and non-prescription products. In contracts that contain prescription products issued as the result of a consultation, revenue also includes medical consultation services and post-consultation service support provided by Affiliated Medical Groups (defined below). Additionally, the Company offers a range of health and wellness products through wholesale partners. Revenue consists of the following (in thousands): Year Ended December 31, 2023 2022 2021 Online Revenue $ 842,381 $ 502,507 $ 259,170 Wholesale Revenue 29,619 24,409 12,708 Total revenue $ 872,000 $ 526,916 $ 271,878 For Online Revenue, the Company defines its customer as an individual who purchases products or services through its websites or mobile applications. For Wholesale Revenue, the Company defines its customer as a wholesale partner, with the exception of consignment arrangements, where its customer is defined as an individual who purchases products through certain third-party platforms. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation primarily include the following performance obligations: access to (i) products, as well as medication adjustments, as applicable, and (ii) consultation services, as well as post-consultation service support, as applicable. The Company’s contracts for prescription refills and contracts that do not contain prescription products have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier or customer warehouse. The Company satisfies its performance obligation for consultation services typically within one day and for post-consultation service support over the contract term. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis. The stand-alone selling price is based on the prices at which the Company separately sells the products and services, as well as market and cost plus estimates. For each of the years ended December 31, 2023, 2022, and 2021, service revenue represented less than 10% of consolidated revenues. To fulfill its promise to customers for contracts that include professional medical consultations, the Company maintains relationships with various “Affiliated Medical Groups,” which are professional corporations or other professional entities owned by licensed physicians and that engage licensed healthcare professionals (physicians, physician assistants, nurse practitioners, and mental health providers; collectively referred to as “Providers” or individually, a “Provider”) to provide consultation services. Refer to Note 12 – Variable Interest Entities. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which Affiliated Medical Group and Provider provides the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, in its sole discretion, sets all listed prices charged on its websites and mobile applications for products and services. Additionally, to fulfill its promise to customers for contracts that include sale of prescription products, the Company maintains relationships with (i) certain third-party pharmacies (“Partner Pharmacies” or individually, a “Partner Pharmacy”) and (ii) XeCare, LLC (“XeCare”) and Apostrophe Pharmacy LLC (“Apostrophe Pharmacy”, and together with XeCare, the “Affiliated Pharmacies”), which are licensed mail order pharmacies providing prescription fulfillment solely to the Company’s customers. The Partner Pharmacies and the Affiliated Pharmacies fill prescription orders for customers who have received a prescription from a prescribing Provider through the Company’s websites and mobile applications. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Partner Pharmacy or Affiliated Pharmacy fills a customer’s prescription; (ii) Partner Pharmacies and Affiliated Pharmacies fill the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; (iv) the Company is responsible for refunds of the prescription medication after transfer of control to the customer; and (v) the Company, in its sole discretion, sets all listed prices charged on its websites and mobile applications for products and services. The Company estimates refunds using the expected value method primarily based on historical refunds granted to customers. The Company updates its estimate at the end of each reporting period and recognizes the estimated amount as contra-revenue with a corresponding refund liability. Sales, value-added, and other taxes are excluded from the transaction price and, therefore, from revenue. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. For online sales, payment for prescription medication and non-prescription products is typically collected from the customer a few days in advance of product shipment in accordance with contract terms, with the exception of prepaid offerings for which payment is collected upfront with subsequent shipments typically occurring quarterly. Contract liabilities are recorded when payments have been received from the customer for undelivered products or services and are recognized as revenue when the performance obligations are later satisfied. Contract liabilities consisting of balances related to customer prepayments are recognized as current deferred revenue on the consolidated balance sheets since the associated revenue will be primarily recognized within the following month, with the exception of post-consultation service support and prepaid offerings which are recognized within the following year. For wholesale arrangements, payments are collected in accordance with contract terms. Cost of Revenue Cost of revenue consists of costs directly attributable to the products shipped and services rendered, including product costs, packaging materials, shipping costs, and labor costs directly related to revenue generating activities. Costs related to free products where there is no expectation of future purchases from a customer and depreciation and amortization on property, equipment, and software are considered to be operating expenses and are excluded from cost of revenue. Stock-Based Compensation The fair value of stock options, equity-classified warrants issued to vendors, restricted stock units (“RSUs”), and performance RSUs (“PRSUs”) are measured at the grant date fair value. The fair value of employee stock options and vendor warrants are generally determined using the Black-Scholes Merton (“BSM”) option-pricing model using various inputs, including estimates of expected volatility, term, risk-free rate, and future dividends. Stock options that were granted to the Company’s CEO with performance and market conditions and earn-out RSUs were valued using the Monte Carlo simulation model. The Company recognizes compensation costs on a straight-line basis over the requisite service period of the employee and vendor, which is generally the vesting term of four years for options, warrants, and RSUs that do not have performance or market conditions. Stock options and RSUs with performance conditions are recognized when it is probable that performance criteria will be achieved and compensation cost is recognized using the accelerated attribution method. The Company accounts for forfeitures as they occur. The Company’s Employee Stock Purchase Plan (“ESPP”) permits eligible employees to purchase the Company’s Class A common stock during pre-specified offering periods at a discount established by the compensation committee. The purchase price is 85% of the lower of the fair market value of the Company’s Class A common stock on the first trading day of the offering period and the fair market value on the purchase date. The ability to purchase shares of the Company’s Class A common stock for a discount represents an option and, therefore, the ESPP is considered a compensatory plan. Accordingly, stock-based compensation expense is determined based on the option’s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the requisite service period, which is the withholding period. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax reporting basis of assets and liabilities. These differences are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company recognizes the effect on deferred income taxes of a change in tax rates in the period that includes the enactment date. The Company provides a valuation allowance, if necessary, to reduce its deferred tax assets to the net amount it believes is more likely than not to be realized. The Company considers both positive and negative evidence, including its historical operating results, forecasts of future taxable income on a jurisdiction-by-jurisdiction basis, and ongoing tax planning strategies, to ascertain the need for a valuation allowance. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. The Company accounts for uncertain tax positions in accordance with the relevant guidance, which prescribes a two-step approach to recognize and measure uncertain tax positions taken or expected to be taken in the income tax return. The first step is to determine whether it is more likely than not that the tax position will be sustained on the basis of the technical merits of the position. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company's policy is to include interest and penalties related to unrecognized tax benefits, if any, wit

Recapitalization

Recapitalization	12 Months Ended
	Dec. 31, 2023
Reverse Recapitalization [Abstract]
Recapitalization	Recapitalization As discussed in Note 1 – Organization, on the Closing Date, OAC completed the acquisition of Hims and acquired 100% of Hims’ shares and Hims received gross proceeds of $197.7 million. Transaction costs of $18.7 million, which consist of legal, accounting, and other professional services directly related to the Merger, are included in additional paid-in capital on the consolidated balance sheet. On the Closing Date, each Hims stockholder received approximately 0.4530 shares of the Company’s Class A common stock, par value $0.0001 per share, for each share of Hims Class A common stock, par value $0.000001 per share, that such stockholder owned (with the CEO receiving 0.4530 shares of the Company’s Class V common stock, par value $0.0001 per share, for each share of Hims Class V common stock, par value $0.000001 per share, that the CEO owned). Each Hims stockholder also received 0.0028 warrants exercisable for the Company’s Class A common stock, for each share of Hims Class A or Class V common stock owned by such stockholder prior to the Merger and earn-out shares at an exchange ratio of 0.0443. As additional consideration, OAC also granted 888,143 OAC Class A common stock warrants (“Parent Warrants”) to Hims’ stockholders, 3,443 Parent Warrants to warrant holders, and approximately 35,000 RSUs to Hims’ option and RSU holders (“Parent Warrant RSUs”). All equity awards of Hims were assumed by OAC and converted into comparable equity awards that are settled or exercisable for shares of the Company’s Class A common stock. As a result, each stock option was converted into an option to purchase shares of the Company’s Class A common stock based on an exchange ratio of 0.4530. Each award of the Hims’ RSUs was converted into RSUs of the Company based on an exchange ratio of 0.4530. Similarly, all outstanding Hims warrants were converted at an exchange ratio of 0.4530. The Merger was accounted for as a reverse recapitalization with Hims as the accounting acquirer and OAC as the acquired company for accounting purposes. Hims was determined to be the accounting acquirer since Hims’ shareholders prior to the Merger had the greatest voting interest in the combined entity, Hims’ shareholders appointed the initial directors of the combined Board of Directors and control future appointments, Hims comprises all of the ongoing operations, and Hims’ senior management directs operations of the combined entity. Accordingly, all historical financial information presented in these consolidated financial statements represents the accounts of Hims and its wholly-owned subsidiaries as if Hims, rather than OAC, is the predecessor to the Company. No step-up basis of intangible assets or goodwill was recorded and net assets were stated at historical cost consistent with the treatment of the transaction as a reverse recapitalization of Hims. The shares and net loss per common share prior to the Merger have been retroactively restated as shares reflecting the exchange ratio established in the Merger (0.4530 Company shares for 1 Hims share). Merger Earn-Out Shares Following the closing of the Merger, holders of Hims’ common stock and outstanding equity awards (including warrant, stock option and RSU holders) had the right to receive up to an aggregate amount of 16,000,000 shares of Company Class A common stock (or equivalent equity award) that would vest (in part) in equal thirds if the trading price of the Company’s Class A common stock was greater than or equal to $15.00, $17.50, and $20.00 for any 10 trading days within any 20-trading day period on or prior to the date that is five years following the Closing Date. These shares of restricted Class A common stock and equivalent equity awards would also vest in connection with an acquisition of the Company if the applicable thresholds were met in any sale (as defined in the Merger Agreement) but subject to the same five-year deadline. In February 2021, all earn-out thresholds were met. In the first quarter of 2021, earn-out awards related to option holders received final approval by the Board of Directors. The earn-out shares are equity classified since they do not meet the liability classification criteria outlined in ASC 480, Distinguishing Liabilities from Equity and are both (i) indexed to the Company’s own shares and (ii) meet the criteria for equity classification. PIPE Investment Concurrently with the execution of the Merger Agreement, OAC entered into subscription agreements on September 30, 2020 with certain investors (the “PIPE Investors”) pursuant to which such investors collectively subscribed for 7,500,000 shares of the Company’s Class A common stock at $10.00 per share for aggregate gross proceeds of $75.0 million (the “PIPE Investment”). The PIPE Investment was consummated substantially concurrently with the closing of the Merger.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions The Company completed two acquisitions in 2021 and accounted for these transactions using the acquisition method with the purchase prices being allocated to tangible and identifiable intangible assets acquired and liabilities assumed based on their respective estimated fair values on the acquisition dates. Fair values were determined using income approaches. Honest Health Limited In June 2021, the Company acquired all of the outstanding equity of Honest Health Limited, which is now Hims & Hers UK Limited (“HHL”), an entity located in the United Kingdom that offers health and wellness products and services, to further expand its operations in the United Kingdom. The purchase price for accounting purposes was $4.8 million, including cash paid upfront and payable in the future, an aggregate of 624,880 shares of the Company’s Class A common stock valued at $1.9 million, and contingent consideration of $1.2 million. The purchase agreement includes up to $10.0 million of potential earn-out payable in cash and stock upon achievement of revenue targets, which is recognized as contingent consideration as well as post-acquisition employment expense. The purchase price for accounting purposes excludes stock and cash consideration to be paid by the Company that is subject to vesting, which is recognized as selling, general, and administrative expenses post-acquisition. See Note 15 – Stockholders’ Equity for additional details. The Company also incurred acquisition costs of $1.9 million directly related to the acquisition, as well as post-acquisition employment expense of $0.7 million, which were recorded within selling, general, and administrative expenses on the consolidated statements of operations and comprehensive loss. The following table summarizes the acquisition date fair values of assets acquired and liabilities assumed (in thousands): Trade name $ 1,470 Other intangible assets 570 Goodwill 2,739 Other net assets 24 Net assets acquired $ 4,803 The excess of the consideration paid over the fair value of the net assets acquired is recorded as goodwill. The acquired goodwill of $2.7 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recognized upon acquisition is not expected to be deductible for U.S. or U.K. income tax purposes. The pro forma financial information, assuming the acquisition had taken place on January 1, 2021, as well as the revenue and earnings generated during the period after the acquisition date, were not material for separate disclosure and, accordingly, have not been presented. Apostrophe In July 2021, the Company acquired all of the outstanding equity of YoDerm, Inc. (“Apostrophe”) , an entity located in the United States that offers health and wellness products and services. The purchase price for accounting purposes was $131.6 million, including cash payments of $48.2 million, an aggregate of 8,074,935 shares of the Company’s Class A common stock valued at $50.7 million, and contingent consideration of $32.7 million. The purchase agreement includes up to $50.0 million of potential earn-out payable in cash upon achievement of revenue targets, which is recognized as contingent consideration or post-acquisition employment expense depending on whether the vesting is contingent on continued employment beyond the acquisition date. The purchase price for accounting purposes excludes stock consideration issued by the Company that is subject to vesting, which is recognized as selling, general, and administrative expenses post-acquisition. See Note 15 – Stockholders’ Equity for additional details . The Company also incurred acquisition costs of $5.0 million directly related to the acquisition, as well as post-acquisition employment expense of $0.5 million, which were recorded within selling, general, and administrative expenses on the consolidated statements of operations and comprehensive loss. The following table summarizes the acquisition date fair values of assets acquired and liabilities assumed (in thousands): Trade name $ 22,700 Other intangible assets 3,140 Goodwill 108,142 Other net liabilities (2,346) Net assets acquired $ 131,636 The fair value measurements of the identified intangible assets were based primarily on significant unobservable inputs and thus represent a Level 3 measurement as defined in ASC 820. The fair values of trade name and developed technology were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets including revenue and cash flow forecasts, customer churn rate, technology life, royalty rate, and discount rate. The fair value of customer relationships was determined using the multi-period excess earnings method which involves forecasting the net earnings expected to be generated by the asset, reducing them by appropriate returns on contributory assets, and then discounting the resulting net cash flows to a present value using an appropriate discount rate. The excess of the consideration paid over the fair value of the net assets acquired is recorded as goodwill. The acquired goodwill of $108.1 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recognized upon acquisition is not expected to be deductible for U.S. income tax purposes. From the acquisition date through December 31, 2021, the Company recognized revenue related to Apostrophe of approximately $11 million. Incremental pro forma revenue attributed to Apostrophe, assuming the acquisition had occurred as of January 1, 2021, would have been approximately $21 million for the year ended December 31, 2021. The pro forma revenue is presented for informational purposes only and does not purport to be indicative of the results of future operations or the results that would have occurred had the transaction taken place on January 1, 2021. Pro forma earnings of Apostrophe, assuming the acquisition had occurred as of January 1, 2021, as well as earnings generated during the period after the acquisition date, were not material for separate disclosure and, accordingly, have not been presented.

Investments

Investments	12 Months Ended
	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Short-term investments as of December 31, 2023, consist of the following (in thousands): Adjusted Unrealized Unrealized Fair U.S. Treasury bills $ 63,809 $ 24 $ — $ 63,833 Corporate bonds 39,152 18 (1) 39,169 Government and government agency 20,624 — (14) 20,610 Asset-backed bonds 705 1 — 706 Total short-term investments $ 124,290 $ 43 $ (15) $ 124,318 Short-term investments as of December 31, 2022, consist of the following (in thousands): Adjusted Unrealized Unrealized Fair Corporate bonds $ 99,672 $ — $ (106) $ 99,566 Government and government agency 33,317 17 (47) 33,287 Total short-term investments $ 132,989 $ 17 $ (153) $ 132,853

Inventory

Inventory	12 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following (in thousands): December 31, 2023 2022 Finished goods $ 15,221 $ 16,477 Raw materials 7,243 5,085 Total inventory $ 22,464 $ 21,562

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2023 2022 Wholesale trade receivables $ 5,705 $ 3,231 Prepaid expenses 10,665 10,392 Other current assets 5,238 1,785 Total prepaid expenses and other current assets $ 21,608 $ 15,408

Property, Equipment, and Softwa

Property, Equipment, and Software, Net	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Equipment, and Software, Net	Property, Equipment, and Software, Net Property, equipment, and software, net consist of the following (in thousands): December 31, 2023 2022 Purchased and internal-use software and website development $ 22,970 $ 12,055 Facility equipment and other tangible property 8,254 3,598 Leasehold improvements 2,256 155 Assets not placed in service 14,907 1,632 Total property, equipment, and software 48,387 17,440 Less: accumulated depreciation and amortization (12,244) (6,241) Total property, equipment, and software, net $ 36,143 $ 11,199 Depreciation and amortization expense for property, equipment, and software was $6.0 million, $3.4 million, and $2.0 million for the years ended December 31, 2023, 2022, and 2021, respectively. Impairment expense for property, equipment, and software was $0.4 million for each of the years ended December 31, 2023 and 2022. There was no impairment expense for the year ended December 31, 2021.

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	Intangible Assets, Net Intangible assets, net as of December 31, 2023 consist of the following (in thousands): Gross Accumulated Amortization and Impairment Net Weighted Trade name $ 24,170 $ (6,880) $ 17,290 7.4 Other 4,803 (3,519) 1,284 5.7 Intangible assets, net $ 28,973 $ (10,399) $ 18,574 7.3 Intangible assets, net as of December 31, 2022 consist of the following (in thousands): Gross Accumulated Net Weighted Trade name $ 24,170 $ (4,504) $ 19,666 8.4 Other 4,581 (2,406) 2,175 4.7 Intangible assets, net $ 28,751 $ (6,910) $ 21,841 8.0 Amortization expense for intangible assets was $3.5 million, $4.1 million, and $2.1 million for the years ended December 31, 2023, 2022, and 2021, respectively. Impairment expense for intangible assets was $0.7 million for the year ended December 31, 2022. There was no impairment expense for the years ended December 31, 2023 and 2021. Amortization that will be charged to expense over the remaining life of the intangible assets subsequent to December 31, 2023 is as follows (in thousands): 2024 $ 2,800 2025 2,611 2026 2,472 2027 2,353 2028 and thereafter 8,338 $ 18,574

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2023
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consist of the following (in thousands): December 31, 2023 2022 Marketing $ 12,331 $ 4,990 Payroll 7,888 4,999 Professional services 5,341 643 Tax 2,009 963 Product and shipping 562 263 Other accruals 841 590 Total accrued liabilities $ 28,972 $ 12,448

Operating Leases

Operating Leases	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Operating Leases	Operating Leases The Company has various operating leases for fulfillment and corporate facilities with lease periods expiring between fiscal years 2025 and 2027. The operating lease agreements provide for rental payments on a graduated basis and for options to renew, which could increase future minimum lease payments if exercised. The Company utilizes the reasonably certain threshold criteria in determining which options it will exercise. During the year ended December 31, 2023, a reassessment due to significant leasehold improvements to the Company’s leased facilities resulted in the remeasurement of the lease liability and an adjustment of $5.7 million to the carrying amount of the corresponding ROU asset. For the years ended December 31, 2023, 2022, and 2021, the Company recorded operating lease costs of $2.4 million, $1.9 million, and $1.8 million, respectively, including variable operating lease costs of $0.4 million for the year ended December 31, 2023 and $0.3 million for each of the years ended December 31, 2022 and 2021. For the years ended December 31, 2023, 2022 and 2021, operating cash flows used for operating leases were $1.9 million, $1.6 million, and $1.5 million, respectively. As of December 31, 2023, the weighted average remaining lease term and weighted average discount rate were 6.2 years and 8.9%, respectively. Future minimum lease payments under the Company's non-cancelable operating lease with an initial lease term in excess of one year subsequent to December 31, 2023 are as follows (in thousands): 2024 $ 2,114 2025 2,207 2026 2,219 2027 1,955 2028 1,696 2029 and thereafter 2,827 Gross lease payments 13,018 Less: imputed interest (3,070) Present value of net future minimum lease payments $ 9,948

Variable Interest Entities

Variable Interest Entities	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities The variable interest entities (“VIEs”) are: (i) the Affiliated Medical Groups; and (ii) the Affiliated Pharmacies. The Company determined that it is the primary beneficiary of these entities for accounting purposes because it has the ability to direct the activities that most significantly affect the entities’ economic performance and has the obligation to absorb the losses. Under the VIE model, the Company presents the results of operations, cash flows, and the financial position of the VIEs as part of the consolidated financial statements of the Company as if the consolidated group were a single economic entity. The assets of the VIEs can only be used to settle the obligations of the VIEs. There is no noncontrolling interest upon consolidation of the entities. The results of operations and cash flows of the VIEs are also included in the Company’s consolidated financial statements. As of December 31, 2023 and 2022, the Company’s consolidated balance sheets included current assets of $24.1 million and $7.5 million, respectively, and total assets of $24.1 million and $7.7 million, respectively, for the VIEs. As of December 31, 2023 and 2022, current and total liabilities were $6.0 million and $3.7 million, respectively. All amounts are after elimination of intercompany transactions, balances, and non-cash impact of operating leases. For the years ended December 31, 2023, 2022, and 2021, the VIEs charged the Company $96.3 million, $64.2 million, and $23.6 million, respectively, for services rendered. For the years ended December 31, 2023, 2022, and 2021 operations of the VIEs generated net income of $3.3 million and $9.1 million, and a net loss of $3.3 million, respectively, inclusive of administrative expenses.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company’s fair value hierarchy for its financial assets that are measured at fair value on a recurring basis as of December 31, 2023, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 42,492 $ — $ — $ 42,492 Short-term investments: U.S. Treasury bills 63,833 — — 63,833 Corporate bonds — 39,169 — 39,169 Government and government agency — 20,610 — 20,610 Asset-backed bonds — 706 — 706 Restricted cash: Money market funds 856 — — 856 Total assets $ 107,181 $ 60,485 $ — $ 167,666 The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 24,606 $ — $ — $ 24,606 Government bonds — 11,315 — 11,315 Short-term investments: Corporate bonds — 99,566 — 99,566 Government and government agency — 33,287 — 33,287 Restricted cash: Money market funds 856 — — 856 Total assets $ 25,462 $ 144,168 $ — $ 169,630 Liabilities Earn-out liability $ — $ — $ 2,975 $ 2,975 Total liabilities $ — $ — $ 2,975 $ 2,975 The fair values of cash, accounts receivable, accounts payable, and accrued liabilities approximated their carrying values as of December 31, 2023 and 2022, due to their short-term nature. All other financial instruments, except for earn-out liability, are valued either based on recent trades of securities in active markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. During the years ended December 31, 2023, 2022, and 2021, the Company had no transfers between levels of the fair value hierarchy of its assets or liabilities measured at fair value. As of December 31, 2022, the earn-out liability, which was solely related to the acquisition of HHL, was classified as a Level 3 fair value measurement containing significant unobservable inputs including estimates of achieving certain revenue targets. At inception, the fair value of the earn-out liability associated with the HHL acquisition was determined based on revenue projections and probability of achievement of revenue targets as evaluated using a Monte Carlo simulation. The following assumptions were used to determine the fair value at inception: HHL Revenue risk-adjusted discount rate 9.1 % Revenue volatility 50.0 % Counterparty discount rate 5.0 % As of December 31, 2023, all contingencies related to the HHL earn-out liability were resolved and the final earn-out payout was determined based on actual revenue from the acquisition date through December 31, 2023. Therefore, the HHL earn-out liability was removed from the fair value hierarchy and reclassified to earn-out payable. The fair value of the earn-out liability was remeasured at each reporting period. This change in fair value was related to contingent consideration and compensation costs (see Note 15 – Stockholders’ Equity) and was recognized in other income (expense) and general and administrative expenses, respectively, on the consolidated statements of operations and comprehensive loss. The change in the fair value of earn-out liabilities is as follows (in thousands): Balance at December 31, 2021 $ 1,999 Change in fair value due to revaluation and service-based vesting 976 Balance at December 31, 2022 2,975 Change in fair value due to revaluation and service-based vesting 4,437 Reclassification to earn-out payable (7,412) Balance at December 31, 2023 $ —

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Obligations The Company has non-cancelable contractual obligations to make future purchases, primarily related to cloud-based software contracts used in operations. As of December 31, 2023, purchase obligations were $7.3 million, with $4.8 million payable in 2024, $2.4 million payable in 2025, and $0.1 million payable in 2026. Lease Commitments Refer to Note 11 – Operating Leases for discussion of the Company’s future lease commitments. Legal Proceedings From time to time, the Company is a party to litigation, various claims, and other legal and administrative proceedings arising in the ordinary course of business. Some of these claims, lawsuits, and other proceedings may involve highly complex issues that are subject to substantial uncertainties, and could result in damages, fines, penalties, non-monetary sanctions, or relief. Management is not currently aware of any matters that are reasonably likely to have a material adverse impact on the Company’s business, financial position, results of operations, or cash flows.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stockholders' Equity	Stockholders’ Equity Common Stock The Company has two classes of common stock, Class A and Class V common stock. The rights are identical, including liquidation and dividend rights, except Class V common stock has additional voting rights. Share Repurchase Program On October 26, 2023, the Board of Directors authorized and approved a share repurchase program pursuant to which the Company may repurchase up to $50.0 million of the Company’s Class A common stock. The program expires on November 8, 2025. The Company intends to use the program to repurchase shares on a discretionary basis from time to time, subject to general business and market conditions and other investment opportunities, through open market purchases, privately negotiated transactions or other means, including through 10b5-1 trading plans. This repurchase program may be suspended or discontinued at any time. During the year ended December 31, 2023, the Company repurchased and retired 237,458 shares of Class A common stock under the program for $2.0 million. As of December 31, 2023, $48.0 million remains available under the program. RSU Releases During the years ended December 31, 2023, 2022, and 2021, the Company released 5,201,501, 2,333,695, and 1,810,545 gross shares of Class A common stock, respectively, upon vesting of RSUs. In connection with the releases, 1,729,045, 701,584, and 620,759 shares of Class A common stock, respectively, were withheld for the payment of employee taxes. 2017 Stock Plan and 2020 Equity Incentive Plan In July 2017, Hims adopted the 2017 Stock Plan (the “2017 Plan”). Under the 2017 Plan, the board of directors of Hims granted awards, including incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSU awards, and other stock awards to employees, directors, and consultants of Hims. In January 2021, in connection with the Merger, the Board of Directors adopted the 2020 Equity Incentive Plan (the “2020 Plan”) and reserved 21,000,000 authorized shares of Class A common stock the Company could issue. In addition, up to 19,000,000 shares of Hims Class A common stock subject to awards granted under the 2017 Plan that were forfeited, expired, or lapsed unexercised or unsettled could be added to the 2020 Plan reserve. Beginning on January 1, 2022 and ending on January 1, 2031, the number of authorized shares of common stock under the 2020 Plan will automatically increase each fiscal year by 5% of the total number of Class A and Class V common stock issued and outstanding on the last day of the preceding fiscal year unless the Board of Directors approves a lesser number. As of the effective date of the 2020 Plan, no further stock awards have been or will be granted under the 2017 Plan. As of December 31, 2022, there were 33,101,677 and 10,963,031 shares of Class A common stock reserved and available for issuance, respectively, under the 2020 Plan. For the year ended December 31, 2023, 89,810 shares of Class A common stock subject to awards granted under the 2017 Plan that were forfeited after the adoption of the 2020 Plan were added to the 2020 Plan reserve. Additionally, on January 1, 2023, 10,421,465 shares of Class A common stock were automatically added to the 2020 Plan reserve. Therefore, as of December 31, 2023, there were 43,612,952 shares of Class A common stock reserved and 12,577,863 shares of Class A common stock available for issuance under the 2020 Stock Plan. There were no more shares available for grant under the 2017 Plan since the 2017 Plan was replaced by the 2020 Plan. 2020 Employee Stock Purchase Plan In January 2021, the Board of Directors adopted the Company’s Employee Stock Purchase Plan (“ESPP”). The total shares of Class A common stock initially reserved under the ESPP is limited to 4,000,000 shares of Class A common stock. Beginning on January 1, 2022 and ending on January 1, 2041 (unless extended by the Board of Directors and approved by the Company’s shareholders), the number of authorized shares of common stock under the ESPP will automatically increase each fiscal year by the lesser of (i) 1% of the total number of Class A and Class V common stock issued and outstanding on the last day of the preceding fiscal year, (ii) 12,000,000 shares of Class A common stock, or (iii) a number of shares of Class A common stock determined by the Board of Directors. As of December 31, 2022, there were 6,047,919 and 5,654,391 shares of Class A common stock reserved and available for issuance, respectively, under the ESPP. There were no shares added to the ESPP reserve on January 1, 2023. Therefore, as of December 31, 2023, there were 6,047,919 shares of Class A common stock reserved for issuance under the ESPP. During the years ended December 31, 2023 and 2022, respectively, the Company issued 594,885 and 393,528 shares of Class A common stock under the ESPP. No shares were issued under the ESPP during the year ended December 31, 2021. As of December 31, 2023, there were 5,059,506 shares of Class A common stock available for issuance under the ESPP. Under the ESPP, eligible employees may purchase the Company’s Class A common stock during pre-specified offering periods at a discount established by the Company’s compensation committee. The purchase price is 85% of the lower of the fair market value of the Company’s Class A common stock on the first trading day of the offering period or the fair market value on the purchase date. Under the ESPP, the Company may specify offering periods with durations of not more than 27 months, and may specify shorter purchase periods within each offering period. Employees participating in the ESPP commence payroll withholdings that accumulate through the end of the respective offering period. As of December 31, 2023, $0.5 million has been withheld via employee payroll deductions for employees who have opted to participate in the purchase periods ending May 2024. As of December 31, 2023, there was $2.0 million of unrecognized stock-based compensation related to the ESPP which is expected to be recognized over a weighted average period of 1.43 years. Stock Options Options for new employees generally vest over four years, with 25% vesting one year after the vesting commencement date and then 1/48th of the total grant vesting monthly thereafter. Options granted to current employees generally vest 1/48th of the total grant monthly over four years. Options granted are exercisable within a period not exceeding ten years from the grant date. On June 17, 2020, the board of directors of Hims granted 3,246,139 and 1,623,070 stock options to the CEO with an exercise price of $2.43 to vest upon either (i) an acquisition of the Company with per share consideration equal to at least $22.99 and $38.31, respectively, or (ii) a per share price on a public stock exchange that is at least equal to $22.99 and $38.31, respectively. The CEO is required to be employed at the time the per share consideration/price is achieved in order to receive the awards, but the awards are not subject to any other service condition. The Company recognizes expense related to these awards based on the fair value and derived service period as measured using a Monte Carlo simulation model, and the expense is accelerated if the requirements outlined in (i) and (ii) above are achieved. The grant date fair value was $16.6 million for these awards. The $22.99 per share price threshold related to awards for the 3,246,139 stock options was achieved in February 2021. As of December 31, 2023, 313,257 of these stock options have been exercised at a weighted average exercise price of $2.43. As of December 31, 2023, there was $0.4 million of remaining compensation expense to be recognized for the remaining 1,623,070 stock options over a period of 0.29 years. On February 24, 2022, the Board of Directors granted 2,085,640 stock options to the CEO with an exercise price of $5.01 that vest in four The grant date fair value of the Company’s stock options granted (excluding the stock options granted to the CEO outlined above) was estimated using the following weighted average assumptions: Year Ended December 31, 2023 2022 2021 Expected term (in years) 6.02 6.02 5.94 Expected volatility 49.9 % 48.0 % 58.6 % Risk-free interest rate 4.2 % 2.0 % 0.9 % Expected dividend yield — % — % — % Option activity (excluding the stock options granted to the CEO outlined above) is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Weighted Aggregate Outstanding at December 31, 2022 14,450 $ 4.68 7.98 $ 35,771 Granted 603 11.53 Exercised (912) 1.74 Forfeited and expired (357) 6.50 Outstanding at December 31, 2023 13,784 5.14 7.14 57,972 Exercisable as of December 31, 2023 9,688 4.55 6.68 45,759 The weighted average grant date fair value of options granted for the years ended December 31, 2023, 2022, and 2021 was $6.09, $2.44, and $6.51 per share, respectively, and the intrinsic value of vested options exercised was $6.2 million, $6.3 million, and $12.6 million, respectively. As of December 31, 2023, there was $15.3 million of unrecognized stock-based compensation related to unvested stock options (excluding the stock options granted to the CEO outlined above) which is expected to be recognized over a weighted average period of 2.04 years. The options outstanding and exercisable as of December 31, 2023 (excluding the stock options granted to the CEO outlined above) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Shares Weighted $0.06 – 0.40 1,422 4.23 1,422 4.23 1.55 – 1.75 760 5.37 760 5.37 2.43 – 3.11 2,751 6.43 2,751 6.43 5.01 – 6.82 5,913 8.18 2,690 8.18 8.13 – 11.53 2,127 7.68 1,499 7.20 12.21 – 15.17 811 7.32 566 7.31 13,784 9,688 The options outstanding and exercisable as of December 31, 2022 (excluding the stock options granted to the CEO outlined above) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Shares Weighted $0.06 – 0.40 1,830 5.21 1,830 5.21 1.55 – 1.75 959 6.43 959 6.43 2.43 – 3.11 3,037 7.50 2,921 7.42 5.01 – 6.82 6,190 9.21 977 9.17 8.13 – 9.41 1,569 8.13 1,301 8.04 12.21 – 15.17 865 8.19 401 8.03 14,450 8,389 RSUs RSUs for new employees generally vest over four years, with 25% vesting one year after the vesting commencement date on the first Company Quarterly Vesting Date (defined below) and the remaining grant vesting quarterly thereafter on the specified vesting dates of March 15, June 15, September 15, and December 15 (each, a “Company Quarterly Vesting Date” or collectively, “Company Quarterly Vesting Dates”). Additional RSUs granted to current employees generally vest quarterly on Company Quarterly Vesting Dates over four years. RSU activity (excluding the performance RSUs outlined below) is as follows (in thousands, except for weighted average grant date fair value): Shares Weighted Average Unvested at December 31, 2022 11,601 $ 6.40 Granted 10,198 9.64 Vested (5,202) 7.54 Forfeited and expired (2,114) 7.40 Unvested at December 31, 2023 14,483 $ 8.08 Included in the above activity are 476,308 earn-out RSUs and 9,478 Parent Warrant RSUs issued to the CEO in January 2021 that vest in accordance with the same market conditions as the CEO stock options, of which 317,539 earn-out RSUs and 6,319 Parent Warrant RSUs have vested as of December 31, 2023. In addition, the Company granted 45,297 RSUs in 2020 and 4,431 earn-out RSUs and 88 Parent Warrant RSUs in January 2021 to a non-executive officer that vest upon meeting certain revenue targets from the sale of specific products, all of which have vested as of December 31, 2023. These grants are also included in the above activity. As of December 31, 2023, $103.8 million of unrecognized stock-based compensation related to unvested RSUs (excluding the performance RSUs outlined below) which is expected to be recognized over a weighted average period of 2.91 years. Performance RSUs On March 1, 2023, the Board of Directors granted awards of 1,115,709 target shares of PRSUs to certain executive officers. As of December 31, 2023, 11,408 shares subject to PRSUs have been forfeited. The PRSUs vest at the end of a three-year period, with the number of shares earned ranging from 0% to 200% of the target, provided that (i) the recipient remains employed at the end of the period and (ii) the Company achieves certain performance metrics related to the 2025 fiscal year. The total grant date fair value of the awards was $12.9 million, which was based on the probable achievement of 100% of the target. The Company will continue to evaluate the likelihood of achieving the performance metrics on a quarterly basis. As of December 31, 2023, there was unrecognized stock-based compensation expense related to unvested PRSUs of $11.5 million, which is expected to be recognized over a weighted average period of 2.21 years. Warrants As of December 31, 2023, there were 462,335 Class A common stock warrants outstanding and exercisable issued to nonemployees in connection with vendor service arrangements, with a weighted average exercise price of $1.75, a weighted average contractual term of 7.01 years, and an aggregate intrinsic value of $3.3 million. Upon the exercise of outstanding warrants, vendors also have the right to receive 45,225 shares of Class A common stock. As of December 31, 2023, all stock-based compensation expense related to vendor warrants and associated earn-out shares has been recognized. As of December 31, 2023, there were 98,723 Class A common stock warrants outstanding and exercisable issued in connection with a historical debt arrangement, with a weighted average exercise price of $6.96, a weighted average contractual term of 6.71 years, and an aggregate intrinsic value of $0.2 million. These debt warrants were settled in additional paid-in capital as a result of their conversion to equity-classified Class A common stock warrants. Stock Subject to Vesting and Earn-out Share Liability In June 2021, the Company granted 447,553 restricted shares of Class A common stock subject to vesting with an aggregate grant date fair value of $5.5 million in connection with the acquisition of HHL. As part of the acquisition of HHL, the Company also recognized an earn-out liability based on the achievement of certain revenue targets. A portion of the earn-out liability is expected to be settled in shares of Class A common stock. Vesting of the restricted shares and a portion of total earn-out payable to specific individuals are contingent on each recipient’s continued employment. Accordingly, the Company has recognized stock-based compensation expense related to these awards for the years ended December 31, 2023, 2022, and 2021. The expense is being recognized over a four-year vesting period with 25% vesting one year after the acquisition date and the remaining vesting quarterly thereafter. As of December 31, 2023, there was unrecognized stock-based compensation expense of $2 million, which will be recognized over a weighted average period of 1.45 years. In July 2021, the Company granted 2,332,557 restricted shares of Class A common stock subject to vesting with an aggregate grant date fair value of $24.2 million in connection with the acquisition of Apostrophe. Vesting of the restricted shares is contingent on each recipient’s continued employment. Accordingly, the Company has recognized stock-based compensation expense related to these awards for the years ended December 31, 2023, 2022, and 2021. The expense is being recognized over a three-year vesting period with 17% vesting 6 months after the acquisition date and the remaining vesting quarterly thereafter. As of December 31, 2023, there was unrecognized stock-based compensation expense of $3.7 million, which will be recognized over a weighted average period of 0.50 years. Stock-Based Compensation Expense The following table summarizes stock-based compensation expense for employees and nonemployees, by category, on the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023, 2022, and 2021 (in thousands): Year Ended December 31, 2023 2022 2021 Marketing $ 5,477 $ 4,648 $ 9,664 Operations and support 6,815 2,684 2,735 Technology and development 7,126 4,327 4,481 General and administrative 46,662 31,158 50,331 Total stock-based compensation expense $ 66,080 $ 42,817 $ 67,211 The Company capitalized $1.7 million, $0.6 million, and $0.7 million of stock-based compensation, as internal-use software for the years ended December 31, 2023, 2022, and 2021 , respectively.

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions For the years ended December 31, 2023, 2022, and 2021, the Company recorded a total of $4.6 million, $3.6 million, and $3.5 million, respectively, within operating expenses on the consolidated statements of operations and comprehensive loss for payments made to Terminal, Inc., a related party company that provides professional services to the Company, primarily to support engineering and operations functions. In addition, for the years ended December 31, 2023, 2022, and 2021, the Company recorded $2.1 million, $1.0 million, and $0.7 million, respectively, within operating expenses on the consolidated statements of operations and comprehensive loss for payments made to Vouched, a related-party company that provides identity verification services.

Basic and Diluted Net Loss per

Basic and Diluted Net Loss per Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share The Company uses the two-class method to calculate net loss per share. No dividends were declared or paid for the years ended December 31, 2023, 2022, and 2021. Undistributed earnings for each period are allocated equally to participating securities based on the contractual participation rights of the security to share in the current earnings as if all current period earnings had been distributed. The Company’s basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average shares of common stock outstanding during periods with undistributed losses. The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts): Year Ended December 31, 2023 2022 2021 Class A Class V Class A Class V Class A Class V Numerator: Net loss attributable to common stockholders $ (22,604) $ (942) $ (62,988) $ (2,690) $ (103,082) $ (4,577) Denominator: Weighted average shares outstanding, basic and diluted 200,967,089 8,377,623 196,138,497 8,377,623 178,840,009 7,941,528 Basic and diluted net loss per share $ (0.11) $ (0.11) $ (0.32) $ (0.32) $ (0.58) $ (0.58) Basic net loss per share is the same as diluted net loss per share attributable to common stockholders for the years ended December 31, 2023, 2022, and 2021, because the inclusion of potential shares of common stock would have been anti-dilutive for the periods presented. The following table discloses weighted-average securities that were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive: Year Ended December 31, 2023 2022 2021 Stock options 21,278,043 20,470,391 16,345,661 RSUs 15,220,986 8,778,890 4,081,026 Common stock issued subject to vesting 1,090,181 2,027,852 1,419,613 PRSUs 928,642 — — Warrants to purchase Class A common stock 561,058 561,058 4,778,003 Common stock issuable under the ESPP 404,648 603,603 136,538 Common stock issued for early exercise of stock options — 70,257 196,431 Redeemable convertible preferred stock — — 4,858,176 Common stock issued for exercise of stock options subject to nonrecourse promissory notes — — 874,312

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Tax	Income Tax For financial reporting purposes, loss before income taxes includes the following (in thousands): Year Ended December 31, 2023 2022 2021 Domestic $ (16,749) $ (62,539) $ (109,393) Foreign (4,822) (3,170) (1,402) Loss before income taxes $ (21,571) $ (65,709) $ (110,795) The provision (benefit) for income taxes consisted of the following (in thousands): Year Ended December 31, 2023 2022 2021 Current: Federal $ 532 $ — $ — State 1,456 563 252 Total current provision 1,988 563 252 Deferred: Federal 12 (339) (2,280) State (25) (110) (966) Foreign — (145) (142) Total deferred benefit (13) (594) (3,388) Total provision (benefit) for income taxes $ 1,975 $ (31) $ (3,136) The provision (benefit) for income taxes differs from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as follows (in thousands): Year Ended December 31, 2023 2022 2021 Tax benefit at federal statutory rate $ (4,530) $ (13,799) $ (23,267) State taxes, net of federal benefits 1,636 (609) (3,498) Transaction costs — (731) 369 Stock-based compensation 1,747 3,897 2,018 Warrants and earn-outs 226 (15) (1,710) Non-deductible officers' compensation 6,386 2,881 8,352 Change in valuation allowance 1,330 7,794 15,971 Research and development credits (5,398) — — Non-deductible expenses 714 613 — Other, net (136) (62) (1,371) Total $ 1,975 $ (31) $ (3,136) The components of deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 53,309 $ 67,214 Research and other credits 3,779 — Capitalized research and development 15,106 — Accrued expenses and reserves 2,164 1,952 Stock-based compensation 3,572 4,079 Inventory 1,890 2,338 Other intangible assets 350 487 Deferred revenue 124 17 Operating lease liabilities 2,615 1,382 Other deferred tax assets 87 553 Total gross deferred tax assets 82,996 78,022 Less valuation allowance (70,506) (69,357) Total deferred tax assets 12,490 8,665 Deferred tax liabilities: Other intangible assets (4,777) (5,623) Fixed assets (1,532) (1,722) Prepaid expenses (1,825) — Operating lease right-of-use assets (2,519) (1,285) Other deferred tax liabilities (1,859) (70) Total deferred tax liabilities (12,512) (8,700) Net deferred tax liabilities $ (22) $ (35) The Company determines its valuation allowance on deferred tax assets by considering both positive and negative evidence to ascertain whether it is more likely than not that deferred tax assets will be realized. Realization of deferred tax assets is dependent upon the generation of future taxable income, if any, the timing and amount of which are uncertain. Due to the Company's history of losses, the Company believes that it is not more likely than not that all of the deferred tax assets can be realized as of December 31, 2023 and 2022. Accordingly, the Company has recorded a valuation allowance against its deferred tax assets. The Company intends to continue maintaining a full valuation allowance on all deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances. However, the Company believes that, within a few years, sufficient positive evidence may become available to reach a conclusion that a significant portion of the valuation allowance will no longer be needed. A release of the valuation allowance would result in the recognition of certain deferred tax assets and a decrease to income tax expense for the period the release is recorded. However, the exact timing and amount of the valuation allowance release are subject to change on the basis of the level of profitability that the Company is actually able to achieve. Additionally, income tax credit estimates could change in the near future due to changes in economic circumstances resulting in the pursuit of additional credits that currently would not be economically beneficial to pursue. The net deferred tax liability is primarily the result of acquired intangible assets for which there is no tax basis. The valuation allowance increased by $1.1 million and $8.0 million during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, the Company has $186.1 million, $154.8 million, and $10.8 million in federal, state, and foreign loss carryforwards (not tax effected), respectively, of which $186.1 million, $17.5 million, and $10.8 million in federal, state, and foreign loss carryforwards do not expire. The remaining state loss carryforwards begin to expire in 2024. As of December 31, 2023, the Company had $6.1 million of federal tax credit carryforwards, prior to the netting of uncertain tax positions, that will begin to expire in 2041. Internal Revenue Code Sections 382 and 383 place a limitation on the amount of taxable income that can be offset by carryforward tax attributes, such as net operating losses or tax credits, after a change in control. Generally, after a change in control, a loss corporation cannot deduct carryforward tax attributes in excess of the limitation prescribed by Sections 382 and 383. Therefore, certain of the Company’s carryforward tax attributes may be subject to an annual limitation regarding their utilization against taxable income in future periods. As a result of issuances of different classes of preferred stock to investors in 2017, 2018, and 2019, the Company triggered “ownership change(s)” as defined in Section 382 and related provisions. Some of the Company’s net operating losses are limited by these ownership changes but the annual limitation does not have a significant impact on the consolidated financial statements. Subsequent ownership changes may subject the Company to annual limitations of its net operating losses. Such annual limitations could result in the expiration of the net operating loss and credit carryforwards before utilization. A full valuation allowance exists on the net operating loss carryforward. The Company did not have any unrecognized tax benefits during the years ended December 31, 2022 and 2021. Changes in unrecognized tax benefits for the year ended December 31, 2023, excluding interest and penalties, were as follows (in thousands): Balance at December 31, 2022 $ — Increases in balances related to prior year tax positions 1,357 Increases in balances related to current year tax positions 956 Balance at December 31, 2023 $ 2,313 Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next 12 months due to tax examination changes, settlement activities, expirations of statute of limitations, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not anticipate any significant changes to its unrecognized tax benefits over the next 12 months. Any adjustments to the Company’s uncertain tax positions would result in an adjustment to its deferred tax asset carryforwards and valuation allowance rather than resulting in an impact to the effective tax rate. During the years ended December 31, 2023, 2022, and 2021, no interest or penalties were required to be recognized relating to unrecognized tax benefits. The Company files income tax returns in the United States, United Kingdom, and various state and local jurisdictions. Due to the net operating loss carryforward, the statute of limitations is open for 2017 and forward for all jurisdictions, none of which are currently under examination by any tax authorities.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In February 2024, the Company entered into a 28-month non-cancelable lease for 29,467 square feet of office, warehouse, and pharmacy space in Gilbert, Arizona. The lease will commence when lessor construction on the space is substantially complete. Total minimum lease payments are $1.0 million, net of rent abatement for an initial two-month period and with an escalation of 4% at the end of the first year. The Company has the option to extend the lease term for a period of one year.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Pay vs Performance Disclosure
Net loss	$ (23,546)	$ (65,678)	$ (107,659)

Insider Trading Arrangements

Insider Trading Arrangements - Officer Trading Arrangement [Member]	3 Months Ended	12 Months Ended
	Dec. 31, 2023 shares	Dec. 31, 2023 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		During the fiscal quarter ended December 31, 2023, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K, except as described in the table below: Name and Title of Insider Adoption, Modification or Termination Applicable Date Duration of Trading Arrangement Rule 10b5-1 Trading Arrangement? (Y / N) (1) Aggregate Number of Securities Subject to the Trading Arrangement Melissa Baird, Chief Operating Officer Adoption 11/21/2023 3/5/2024 - 9/5/2024 Y 370,125 Andrew Dudum, Chief Executive Officer Adoption 11/29/2023 3/1/2024 - 11/29/2024 Y 3,000,000 Lynne Chou O’Keefe, Director Adoption 12/12/2023 6/17/2024 - 12/17/2024 Y 49,843 Michael Chi, Chief Marketing Officer Adoption 12/07/2023 3/7/2024 - 9/18/2024 Y 939,288 Michael Chi, Chief Marketing Officer Termination (2) 12/15/2023 3/7/2024 - 9/18/2024 Y 939,288 ______________ (1) Denotes whether the trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) when adopted. (2)
Rule 10b5-1 Arrangement Adopted	true
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	true
Non-Rule 10b5-1 Arrangement Terminated	false
Melissa Baird [Member]
Trading Arrangements, by Individual
Name	Melissa Baird
Title	Chief Operating Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	11/21/2023
Arrangement Duration	184 days
Aggregate Available	370,125	370,125
Andrew Dudum [Member]
Trading Arrangements, by Individual
Name	Andrew Dudum
Title	Chief Executive Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	11/29/2023
Arrangement Duration	273 days
Aggregate Available	3,000,000	3,000,000
Lynne Chou O'Keefe [Member]
Trading Arrangements, by Individual
Name	Lynne Chou O’Keefe
Title	Director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	12/12/2023
Arrangement Duration	183 days
Aggregate Available	49,843	49,843
Michael Chi [Member]
Trading Arrangements, by Individual
Name	Michael Chi
Title	Chief Marketing Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	12/07/2023
Rule 10b5-1 Arrangement Terminated	true
Termination Date	12/15/2023
Arrangement Duration	195 days
Aggregate Available	939,288	939,288

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	The accompanying consolidated financial statements have been prepared pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities for which it is the primary beneficiary. All intercompany transactions and balances have been eliminated in the consolidated financial statements herein.
Use of Estimates	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and accompanying notes. The more significant estimates, judgments, and assumptions by management include, among others, valuation of inventory, valuation and recognition of stock-based compensation expense, valuation of contingent consideration in business combinations, purchase price allocation for business combinations, estimates used in the capitalization of website and mobile application development and internal-use software costs, and judgments relating to impairment triggering events for long-lived assets. Management believes that the estimates, judgments, and assumptions upon which it relies are reasonable based upon information available to it at the time that these estimates, judgments, and assumptions were made. Actual results experienced by the Company may differ from management’s estimates. To the extent that there are material differences between these estimates and actual results, the Company’s consolidated financial statements will be affected.
Risks and Uncertainties	The Company’s business, operations, and financial results are subject to various risks and uncertainties, including adverse United States economic conditions, legal restrictions, changing laws for medical services and prescription products, decisions to outsource or modify portions of its supply chain, and competition in its industry, and of which could adversely affect its business, financial condition, results of operations, and cash flows. These significant factors, among others, could cause the Company’s future results to differ materially from the consolidated financial statements.
Concentration Risk	The Company’s financial instruments that are potentially exposed to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, investments, and accounts receivable. The Company maintains its cash, cash equivalents, short-term investments, and restricted cash with high-quality financial institutions with investment-grade ratings. The majority of the cash balances are with U.S. banks and are insured to the extent defined by the Federal Deposit Insurance Corporation.
Foreign Currency Translation	The Company’s consolidated financial statements are presented in U.S. dollars. Adjustments resulting from translating foreign functional currency financial statements into U.S. dollars are presented as foreign currency translation adjustments, a component of other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss.
Business Combinations	The Company accounts for its business combinations using the acquisition method of accounting. The purchase price is attributed to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company’s consolidated financial statements from the date of acquisition. When the Company issues stock-based or cash awards to an acquired company’s shareholders, the Company evaluates whether the awards are consideration or compensation for post-acquisition services. The evaluation includes, among other things, whether the vesting of the awards is contingent on the continued employment of the acquired company’s stockholders beyond the acquisition date. If continued employment is required for vesting, the awards are treated as compensation for post-acquisition services and recognized as expense over the requisite service period. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain assumed obligations. Any acquired assets from a business combination including intangible assets subject to amortization are continuously monitored and reviewed for potential impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In such cases, recoverability of assets to be held and used is assessed by comparing the carrying amount of assets with their future underlying net undiscounted cash flows without interest charges. If such assets are considered to be impaired, an impairment is recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets.
Segment Reporting	The Company is managed as a single operating segment on a consolidated basis, inclusive of acquisitions. The Company determined that the Chief Executive Officer (“CEO”) is the chief operating decision maker as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions and managing the organization at a consolidated level.
Cash, Cash Equivalents, and Restricted Cash	The Company considers all highly liquid investments purchased with an original maturity or remaining maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash and cash equivalents with financial institutions. The restricted cash balance comprises cash collateral that is held by the Company’s primary financial institution to secure a letter of credit issued as a security deposit for the Company’s warehouse facility in New Albany, Ohio.
Investments	Available-for-sale debt instruments with original maturities at the date of purchase greater than three months and remaining maturities of less than one year are classified as short-term investments. Available-for-sale debt instruments with original maturities at the date of purchase and remaining maturities of greater than one year are classified as long-term investments. The Company intends to sell such investments, if any, at or close to maturity. The investments are designated as available-for-sale and are reported at fair value, with unrealized gains and losses, net of tax, recorded in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss, except for other-than-temporary impairments and credit losses. The Company determines the cost of the investment sold based on specific identification at the individual security level. The Company records the interest income and realized gains and losses on the sale of these instruments within other income (expense), net on the consolidated statements of operations and comprehensive loss.
Other-Than-Temporary Impairment and Credit Losses	The Company adopted ASC Topic 326 for the year ended December 31, 2021, and considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company’s available-for-sale securities for the years ended December 31, 2023, 2022, or 2021 were caused by fluctuations in market value and interest rates as a result of the economic environment. The Company concluded that an allowance for credit losses for its available-for-sale securities was unnecessary as of December 31, 2023 and 2022 because the decline in the market value was attributable to changes in market conditions and not credit quality, and that it is neither management’s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. There was no realized gain or loss on available-for-sale securities in the periods presented.
Fair Value of Financial Instruments	The fair value of a financial instrument is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities subject to ongoing fair value measurement are categorized and disclosed into one of the three categories depending on observable or unobservable inputs employed in the measurement. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. • Level 2: Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. • Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Inventory	Inventory primarily consists of finished goods and raw materials that are located at Company-managed and third-party fulfillment warehouses and pharmacies. Inventory is stated at the lower of cost and net realizable value and inventory cost is determined by the weighted average cost method. The Company reserves for expired, slow-moving, and excess inventory by estimating the net realizable value based on the potential future use of such inventory. Management monitors inventory to identify events that would require impairment due to slow-moving, expired, or obsolete inventory and reduces the value of inventory when required. Obsolete inventory balances are written off against the inventory allowance when management determines that the inventory cannot be sold.
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of balances related to prepayments or vendor deposits for insurance, marketing, software, inventory and other operating costs, and trade and other accounts receivables. Prepaid expenses are recorded when payment has been made in advance for goods and services. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Receivables are stated at amounts estimated by management to be equal to their net realizable values. The allowance for doubtful accounts is the Company's best estimate of the amount of expected credit losses on its accounts receivable. The expectation of collectability is based on the Company's review of credit profiles of customers, contractual terms and conditions, current economic trends, and historical payment experience. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and an allowance is recorded accordingly. Account balances are written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
Property, Equipment, and Software, Net	Property, equipment, and software consist of purchased and internal-use software and website development, facility equipment and other tangible property, leasehold improvements, and assets not placed in service. Property, equipment, and software are depreciated or amortized using the straight-line method over the estimated useful lives ranging from two Capitalizable website and mobile application development and internal-use software costs are recorded at cost, less amortization. The costs incurred during the website application and infrastructure stages as well as costs incurred during the graphics and content development stages are capitalized; all other costs are expensed as incurred. In addition, the Company incurs costs to develop software for internal use. The costs incurred during the application development phase are capitalized until the project is completed and the asset is ready for intended use. All costs that relate to the preliminary project and post-implementation operation phases of development are expensed as incurred.
Goodwill	Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized but is tested for impairment annually in the fourth quarter or more frequently if events or changes in circumstances indicate that the asset may be impaired. The Company operates as one reporting unit. When testing goodwill for impairment, the Company may first perform an optional qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company will recognize an impairment loss in an amount equal to that excess but limited to the total amount of goodwill.
Intangible Assets	Intangible assets, net primarily includes trade name, customer relationships, and developed technology. The Company amortizes such definite-lived intangible assets on a straight-line basis over the assets’ estimated useful lives of one
Impairment of Long-Lived Assets	Long-lived assets include property and equipment, website and mobile application development and internal-use software, and intangible assets subject to amortization. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In such cases, recoverability of assets to be held and used is assessed by comparing the carrying amount of assets with their future underlying net undiscounted cash flows without interest charges. If such assets are considered to be impaired, an impairment is recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets. The Company recognized $0.4 million and $1.1 million of impairment charges on long-lived assets during the years ended December 31, 2023 and 2022 in general and administrative expenses on the consolidated statements of operations and comprehensive loss. There were no impairment charges on long-lived assets during the year ended December 31, 2021.
Operating Leases	The Company determines if an arrangement contains a lease at inception based on whether there is identified property, plant, or equipment and whether the Company controls the use of the identified asset throughout the period of use. The Company leases facilities for fulfillment and corporate purposes under non-cancelable operating leases with expiration dates between fiscal years 2025 and 2027. The Company's operating leases are reflected in the operating lease right-of-use (“ROU”) assets and in the operating lease liabilities in the accompanying consolidated balance sheets. The operating lease ROU assets represent the Company’s right to use the underlying assets for the lease terms and the lease liabilities represent the Company’s obligation to make lease payments arising from the leases. The operating lease ROU assets and lease liabilities are recognized at each lease’s inception date based on the present value of lease payments over the lease term discounted based on the more readily determinable of (i) the rate implicit in the lease or (ii) the Company’s incremental borrowing rate, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease. Because the Company’s operating leases do not provide an implicit rate, the Company estimates its incremental borrowing rate at the lease commencement date for borrowings with a similar term. The Company’s operating lease ROU assets are measured based on the corresponding operating lease liability adjusted for (i) payments made to the lessor at or before the commencement date, (ii) initial direct costs incurred, and (iii) tenant incentives under the lease. The Company does not assume renewals or early terminations unless it is reasonably certain to exercise these options at commencement. The Company monitors for events or changes in circumstances that require a reassessment of its leases. When a reassessment results in the remeasurement of a lease liability, an adjustment is made to the carrying amount of the corresponding ROU asset. The Company does not allocate consideration between lease and non-lease components. The Company's lease agreements contain variable costs such as common area maintenance, operating expenses, or other costs. Variable lease payments are recognized in the period in which the obligation for those payments are incurred. In addition, the Company does not recognize ROU assets or operating lease liabilities for leases with a term of 12 months or less of all asset classes. Operating lease expense is recognized on a straight-line basis over each lease term.
Revenue Recognition	The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. The Company’s consolidated revenue primarily comprises online sales of health and wellness products and services through the Company’s websites and mobile applications, including prescription and non-prescription products. In contracts that contain prescription products issued as the result of a consultation, revenue also includes medical consultation services and post-consultation service support provided by Affiliated Medical Groups (defined below). Additionally, the Company offers a range of health and wellness products through wholesale partners. For Online Revenue, the Company defines its customer as an individual who purchases products or services through its websites or mobile applications. For Wholesale Revenue, the Company defines its customer as a wholesale partner, with the exception of consignment arrangements, where its customer is defined as an individual who purchases products through certain third-party platforms. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation primarily include the following performance obligations: access to (i) products, as well as medication adjustments, as applicable, and (ii) consultation services, as well as post-consultation service support, as applicable. The Company’s contracts for prescription refills and contracts that do not contain prescription products have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier or customer warehouse. The Company satisfies its performance obligation for consultation services typically within one day and for post-consultation service support over the contract term. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis. The stand-alone selling price is based on the prices at which the Company separately sells the products and services, as well as market and cost plus estimates. For each of the years ended December 31, 2023, 2022, and 2021, service revenue represented less than 10% of consolidated revenues. To fulfill its promise to customers for contracts that include professional medical consultations, the Company maintains relationships with various “Affiliated Medical Groups,” which are professional corporations or other professional entities owned by licensed physicians and that engage licensed healthcare professionals (physicians, physician assistants, nurse practitioners, and mental health providers; collectively referred to as “Providers” or individually, a “Provider”) to provide consultation services. Refer to Note 12 – Variable Interest Entities. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which Affiliated Medical Group and Provider provides the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, in its sole discretion, sets all listed prices charged on its websites and mobile applications for products and services. Additionally, to fulfill its promise to customers for contracts that include sale of prescription products, the Company maintains relationships with (i) certain third-party pharmacies (“Partner Pharmacies” or individually, a “Partner Pharmacy”) and (ii) XeCare, LLC (“XeCare”) and Apostrophe Pharmacy LLC (“Apostrophe Pharmacy”, and together with XeCare, the “Affiliated Pharmacies”), which are licensed mail order pharmacies providing prescription fulfillment solely to the Company’s customers. The Partner Pharmacies and the Affiliated Pharmacies fill prescription orders for customers who have received a prescription from a prescribing Provider through the Company’s websites and mobile applications. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Partner Pharmacy or Affiliated Pharmacy fills a customer’s prescription; (ii) Partner Pharmacies and Affiliated Pharmacies fill the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; (iv) the Company is responsible for refunds of the prescription medication after transfer of control to the customer; and (v) the Company, in its sole discretion, sets all listed prices charged on its websites and mobile applications for products and services. The Company estimates refunds using the expected value method primarily based on historical refunds granted to customers. The Company updates its estimate at the end of each reporting period and recognizes the estimated amount as contra-revenue with a corresponding refund liability. Sales, value-added, and other taxes are excluded from the transaction price and, therefore, from revenue. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. For online sales, payment for prescription medication and non-prescription products is typically collected from the customer a few days in advance of product shipment in accordance with contract terms, with the exception of prepaid offerings for which payment is collected upfront with subsequent shipments typically occurring quarterly. Contract liabilities are recorded when payments have been received from the customer for undelivered products or services and are recognized as revenue when the performance obligations are later satisfied. Contract liabilities consisting of balances related to customer prepayments are recognized as current deferred revenue on the consolidated balance sheets since the associated revenue will be primarily recognized within the following month, with the exception of post-consultation service support and prepaid offerings which are recognized within the following year. For wholesale arrangements, payments are collected in accordance with contract terms.
Cost of Revenue	Cost of revenue consists of costs directly attributable to the products shipped and services rendered, including product costs, packaging materials, shipping costs, and labor costs directly related to revenue generating activities. Costs related to free products where there is no expectation of future purchases from a customer and depreciation and amortization on property, equipment, and software are considered to be operating expenses and are excluded from cost of revenue.
Stock-based Compensation	The fair value of stock options, equity-classified warrants issued to vendors, restricted stock units (“RSUs”), and performance RSUs (“PRSUs”) are measured at the grant date fair value. The fair value of employee stock options and vendor warrants are generally determined using the Black-Scholes Merton (“BSM”) option-pricing model using various inputs, including estimates of expected volatility, term, risk-free rate, and future dividends. Stock options that were granted to the Company’s CEO with performance and market conditions and earn-out RSUs were valued using the Monte Carlo simulation model. The Company recognizes compensation costs on a straight-line basis over the requisite service period of the employee and vendor, which is generally the vesting term of four years for options, warrants, and RSUs that do not have performance or market conditions. Stock options and RSUs with performance conditions are recognized when it is probable that performance criteria will be achieved and compensation cost is recognized using the accelerated attribution method. The Company accounts for forfeitures as they occur. The Company’s Employee Stock Purchase Plan (“ESPP”) permits eligible employees to purchase the Company’s Class A common stock during pre-specified offering periods at a discount established by the compensation committee. The purchase price is 85% of the lower of the fair market value of the Company’s Class A common stock on the first trading day of the offering period and the fair market value on the purchase date. The ability to purchase shares of the Company’s Class A common stock for a discount represents an option and, therefore, the ESPP is considered a compensatory plan. Accordingly, stock-based compensation expense is determined based on the option’s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the requisite service period, which is the withholding period.
Income Taxes	The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax reporting basis of assets and liabilities. These differences are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company recognizes the effect on deferred income taxes of a change in tax rates in the period that includes the enactment date. The Company provides a valuation allowance, if necessary, to reduce its deferred tax assets to the net amount it believes is more likely than not to be realized. The Company considers both positive and negative evidence, including its historical operating results, forecasts of future taxable income on a jurisdiction-by-jurisdiction basis, and ongoing tax planning strategies, to ascertain the need for a valuation allowance. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes.
Employee Benefit Plan	The Company has established a 401(k) plan that qualifies as a deferred compensation arrangement under Section 401 of the Internal Revenue Code. The Company contributes 50% of eligible employee’s elective deferrals up to an annual maximum of three thousand dollars per employee.
Advertising	For the years ended December 31, 2023, 2022, and 2021, advertising costs for customer acquisition and content production were $390.3 million, $235.6 million, and $103.5 million, respectively. Customer acquisition expenses are charged to expense as incurred and recorded within marketing expense on the consolidated statements of operations and comprehensive loss. The Company defers production costs associated with advertising campaigns until the date of first showing.
Other Comprehensive Income (Loss)	The Company’s other comprehensive income (loss) is impacted by foreign currency translation and available-for-sale investment fair value adjustments. The impact of foreign currency translation is affected by the translation of assets and liabilities of the Company’s United Kingdom foreign subsidiary, which is denominated in pounds sterling. The primary assets and liabilities affecting the adjustments are cash and cash equivalents, facility equipment, other assets, accounts payable and accrued liabilities, and long-term liabilities. The impact of available-for-sale securities is primarily affected by unrecognized gains and losses related to fluctuations in the fair market value of the securities
Liquidity	To date, the Company has financed its operations principally from the sale of its equity, revenue from the Hims & Hers platform, and the incurrence of indebtedness. The Company has historically incurred negative cash flows from operating activities and significant losses from operations. While the Company had positive cash flows from operating activities for the year ended December 31, 2023, the Company may incur operating losses in the future due to continued investments into its business. The Company believes that its existing cash and investment balances are sufficient for the Company to meet its obligations through at least one year from the date of issuance of the consolidated financial statements. Management considers that there are no conditions or events in the aggregate that raise substantial doubt about the entity’s ability to continue as a going concern for a period of at least one year from the date the consolidated financial statements are issued.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . The amendments in this Update expand reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for all public entities for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . The amendments in this Update expand income tax disclosure requirements, primarily through enhanced disclosures related to income taxes paid and the rate reconciliation. ASU 2023-09 is effective for all public entities for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments should be applied on a prospective basis and retrospective application is permitted. The Company is evaluating the method of adoption and the impact of this guidance on its consolidated financial statements and related disclosures.
Fair Value Measurements	The fair value measurements of the identified intangible assets were based primarily on significant unobservable inputs and thus represent a Level 3 measurement as defined in ASC 820. The fair values of trade name and developed technology were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets including revenue and cash flow forecasts, customer churn rate, technology life, royalty rate, and discount rate. The fair value of customer relationships was determined using the multi-period excess earnings method which involves forecasting the net earnings expected to be generated by the asset, reducing them by appropriate returns on contributory assets, and then discounting the resulting net cash flows to a present value using an appropriate discount rate.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Capitalized Computer Software, Expected Amortization	The following table summarizes the estimated amortization of website development and internal-use software costs subsequent to December 31, 2023 (in thousands): 2024 $ 6,461 2025 5,058 2026 2,568 Total $ 14,087
Disaggregation of Revenue	Revenue consists of the following (in thousands): Year Ended December 31, 2023 2022 2021 Online Revenue $ 842,381 $ 502,507 $ 259,170 Wholesale Revenue 29,619 24,409 12,708 Total revenue $ 872,000 $ 526,916 $ 271,878

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the acquisition date fair values of assets acquired and liabilities assumed (in thousands): Trade name $ 1,470 Other intangible assets 570 Goodwill 2,739 Other net assets 24 Net assets acquired $ 4,803 The following table summarizes the acquisition date fair values of assets acquired and liabilities assumed (in thousands): Trade name $ 22,700 Other intangible assets 3,140 Goodwill 108,142 Other net liabilities (2,346) Net assets acquired $ 131,636

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of short term investments	Short-term investments as of December 31, 2023, consist of the following (in thousands): Adjusted Unrealized Unrealized Fair U.S. Treasury bills $ 63,809 $ 24 $ — $ 63,833 Corporate bonds 39,152 18 (1) 39,169 Government and government agency 20,624 — (14) 20,610 Asset-backed bonds 705 1 — 706 Total short-term investments $ 124,290 $ 43 $ (15) $ 124,318 Short-term investments as of December 31, 2022, consist of the following (in thousands): Adjusted Unrealized Unrealized Fair Corporate bonds $ 99,672 $ — $ (106) $ 99,566 Government and government agency 33,317 17 (47) 33,287 Total short-term investments $ 132,989 $ 17 $ (153) $ 132,853

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventory consists of the following (in thousands): December 31, 2023 2022 Finished goods $ 15,221 $ 16,477 Raw materials 7,243 5,085 Total inventory $ 22,464 $ 21,562

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2023 2022 Wholesale trade receivables $ 5,705 $ 3,231 Prepaid expenses 10,665 10,392 Other current assets 5,238 1,785 Total prepaid expenses and other current assets $ 21,608 $ 15,408

Property, Equipment, and Soft_2

Property, Equipment, and Software, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, equipment, and software, net consist of the following (in thousands): December 31, 2023 2022 Purchased and internal-use software and website development $ 22,970 $ 12,055 Facility equipment and other tangible property 8,254 3,598 Leasehold improvements 2,256 155 Assets not placed in service 14,907 1,632 Total property, equipment, and software 48,387 17,440 Less: accumulated depreciation and amortization (12,244) (6,241) Total property, equipment, and software, net $ 36,143 $ 11,199

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets, net as of December 31, 2023 consist of the following (in thousands): Gross Accumulated Amortization and Impairment Net Weighted Trade name $ 24,170 $ (6,880) $ 17,290 7.4 Other 4,803 (3,519) 1,284 5.7 Intangible assets, net $ 28,973 $ (10,399) $ 18,574 7.3 Intangible assets, net as of December 31, 2022 consist of the following (in thousands): Gross Accumulated Net Weighted Trade name $ 24,170 $ (4,504) $ 19,666 8.4 Other 4,581 (2,406) 2,175 4.7 Intangible assets, net $ 28,751 $ (6,910) $ 21,841 8.0
Finite-lived Intangible Assets Amortization Expense	Amortization that will be charged to expense over the remaining life of the intangible assets subsequent to December 31, 2023 is as follows (in thousands): 2024 $ 2,800 2025 2,611 2026 2,472 2027 2,353 2028 and thereafter 8,338 $ 18,574

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): December 31, 2023 2022 Marketing $ 12,331 $ 4,990 Payroll 7,888 4,999 Professional services 5,341 643 Tax 2,009 963 Product and shipping 562 263 Other accruals 841 590 Total accrued liabilities $ 28,972 $ 12,448

Operating Leases (Tables)

Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Lessee, Operating Lease, Liability, Maturity	Future minimum lease payments under the Company's non-cancelable operating lease with an initial lease term in excess of one year subsequent to December 31, 2023 are as follows (in thousands): 2024 $ 2,114 2025 2,207 2026 2,219 2027 1,955 2028 1,696 2029 and thereafter 2,827 Gross lease payments 13,018 Less: imputed interest (3,070) Present value of net future minimum lease payments $ 9,948

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The Company’s fair value hierarchy for its financial assets that are measured at fair value on a recurring basis as of December 31, 2023, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 42,492 $ — $ — $ 42,492 Short-term investments: U.S. Treasury bills 63,833 — — 63,833 Corporate bonds — 39,169 — 39,169 Government and government agency — 20,610 — 20,610 Asset-backed bonds — 706 — 706 Restricted cash: Money market funds 856 — — 856 Total assets $ 107,181 $ 60,485 $ — $ 167,666 The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 24,606 $ — $ — $ 24,606 Government bonds — 11,315 — 11,315 Short-term investments: Corporate bonds — 99,566 — 99,566 Government and government agency — 33,287 — 33,287 Restricted cash: Money market funds 856 — — 856 Total assets $ 25,462 $ 144,168 $ — $ 169,630 Liabilities Earn-out liability $ — $ — $ 2,975 $ 2,975 Total liabilities $ — $ — $ 2,975 $ 2,975
Fair Value Measurement Inputs and Valuation Techniques	The following assumptions were used to determine the fair value at inception: HHL Revenue risk-adjusted discount rate 9.1 % Revenue volatility 50.0 % Counterparty discount rate 5.0 %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The change in the fair value of earn-out liabilities is as follows (in thousands): Balance at December 31, 2021 $ 1,999 Change in fair value due to revaluation and service-based vesting 976 Balance at December 31, 2022 2,975 Change in fair value due to revaluation and service-based vesting 4,437 Reclassification to earn-out payable (7,412) Balance at December 31, 2023 $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The grant date fair value of the Company’s stock options granted (excluding the stock options granted to the CEO outlined above) was estimated using the following weighted average assumptions: Year Ended December 31, 2023 2022 2021 Expected term (in years) 6.02 6.02 5.94 Expected volatility 49.9 % 48.0 % 58.6 % Risk-free interest rate 4.2 % 2.0 % 0.9 % Expected dividend yield — % — % — %
Share-based Payment Arrangement, Option, Activity	Option activity (excluding the stock options granted to the CEO outlined above) is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Weighted Aggregate Outstanding at December 31, 2022 14,450 $ 4.68 7.98 $ 35,771 Granted 603 11.53 Exercised (912) 1.74 Forfeited and expired (357) 6.50 Outstanding at December 31, 2023 13,784 5.14 7.14 57,972 Exercisable as of December 31, 2023 9,688 4.55 6.68 45,759
Share-based Payment Arrangement, Option, Exercise Price Range	The options outstanding and exercisable as of December 31, 2023 (excluding the stock options granted to the CEO outlined above) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Shares Weighted $0.06 – 0.40 1,422 4.23 1,422 4.23 1.55 – 1.75 760 5.37 760 5.37 2.43 – 3.11 2,751 6.43 2,751 6.43 5.01 – 6.82 5,913 8.18 2,690 8.18 8.13 – 11.53 2,127 7.68 1,499 7.20 12.21 – 15.17 811 7.32 566 7.31 13,784 9,688 The options outstanding and exercisable as of December 31, 2022 (excluding the stock options granted to the CEO outlined above) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Shares Weighted $0.06 – 0.40 1,830 5.21 1,830 5.21 1.55 – 1.75 959 6.43 959 6.43 2.43 – 3.11 3,037 7.50 2,921 7.42 5.01 – 6.82 6,190 9.21 977 9.17 8.13 – 9.41 1,569 8.13 1,301 8.04 12.21 – 15.17 865 8.19 401 8.03 14,450 8,389
Share-based Payment Arrangement, Restricted Stock Unit, Activity	RSU activity (excluding the performance RSUs outlined below) is as follows (in thousands, except for weighted average grant date fair value): Shares Weighted Average Unvested at December 31, 2022 11,601 $ 6.40 Granted 10,198 9.64 Vested (5,202) 7.54 Forfeited and expired (2,114) 7.40 Unvested at December 31, 2023 14,483 $ 8.08
Share-based Payment Arrangement, Expensed and Capitalized, Amount	The following table summarizes stock-based compensation expense for employees and nonemployees, by category, on the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023, 2022, and 2021 (in thousands): Year Ended December 31, 2023 2022 2021 Marketing $ 5,477 $ 4,648 $ 9,664 Operations and support 6,815 2,684 2,735 Technology and development 7,126 4,327 4,481 General and administrative 46,662 31,158 50,331 Total stock-based compensation expense $ 66,080 $ 42,817 $ 67,211

Basic and Diluted Net Loss pe_2

Basic and Diluted Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts): Year Ended December 31, 2023 2022 2021 Class A Class V Class A Class V Class A Class V Numerator: Net loss attributable to common stockholders $ (22,604) $ (942) $ (62,988) $ (2,690) $ (103,082) $ (4,577) Denominator: Weighted average shares outstanding, basic and diluted 200,967,089 8,377,623 196,138,497 8,377,623 178,840,009 7,941,528 Basic and diluted net loss per share $ (0.11) $ (0.11) $ (0.32) $ (0.32) $ (0.58) $ (0.58)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table discloses weighted-average securities that were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive: Year Ended December 31, 2023 2022 2021 Stock options 21,278,043 20,470,391 16,345,661 RSUs 15,220,986 8,778,890 4,081,026 Common stock issued subject to vesting 1,090,181 2,027,852 1,419,613 PRSUs 928,642 — — Warrants to purchase Class A common stock 561,058 561,058 4,778,003 Common stock issuable under the ESPP 404,648 603,603 136,538 Common stock issued for early exercise of stock options — 70,257 196,431 Redeemable convertible preferred stock — — 4,858,176 Common stock issued for exercise of stock options subject to nonrecourse promissory notes — — 874,312

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	For financial reporting purposes, loss before income taxes includes the following (in thousands): Year Ended December 31, 2023 2022 2021 Domestic $ (16,749) $ (62,539) $ (109,393) Foreign (4,822) (3,170) (1,402) Loss before income taxes $ (21,571) $ (65,709) $ (110,795)
Schedule of Components of Income Tax Expense (Benefit)	The provision (benefit) for income taxes consisted of the following (in thousands): Year Ended December 31, 2023 2022 2021 Current: Federal $ 532 $ — $ — State 1,456 563 252 Total current provision 1,988 563 252 Deferred: Federal 12 (339) (2,280) State (25) (110) (966) Foreign — (145) (142) Total deferred benefit (13) (594) (3,388) Total provision (benefit) for income taxes $ 1,975 $ (31) $ (3,136)
Schedule of Effective Income Tax Rate Reconciliation	The provision (benefit) for income taxes differs from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as follows (in thousands): Year Ended December 31, 2023 2022 2021 Tax benefit at federal statutory rate $ (4,530) $ (13,799) $ (23,267) State taxes, net of federal benefits 1,636 (609) (3,498) Transaction costs — (731) 369 Stock-based compensation 1,747 3,897 2,018 Warrants and earn-outs 226 (15) (1,710) Non-deductible officers' compensation 6,386 2,881 8,352 Change in valuation allowance 1,330 7,794 15,971 Research and development credits (5,398) — — Non-deductible expenses 714 613 — Other, net (136) (62) (1,371) Total $ 1,975 $ (31) $ (3,136)
Schedule of Deferred Tax Assets and Liabilities	The components of deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 53,309 $ 67,214 Research and other credits 3,779 — Capitalized research and development 15,106 — Accrued expenses and reserves 2,164 1,952 Stock-based compensation 3,572 4,079 Inventory 1,890 2,338 Other intangible assets 350 487 Deferred revenue 124 17 Operating lease liabilities 2,615 1,382 Other deferred tax assets 87 553 Total gross deferred tax assets 82,996 78,022 Less valuation allowance (70,506) (69,357) Total deferred tax assets 12,490 8,665 Deferred tax liabilities: Other intangible assets (4,777) (5,623) Fixed assets (1,532) (1,722) Prepaid expenses (1,825) — Operating lease right-of-use assets (2,519) (1,285) Other deferred tax liabilities (1,859) (70) Total deferred tax liabilities (12,512) (8,700) Net deferred tax liabilities $ (22) $ (35)
Schedule of Unrecognized Tax Benefits Roll Forward	Changes in unrecognized tax benefits for the year ended December 31, 2023, excluding interest and penalties, were as follows (in thousands): Balance at December 31, 2022 $ — Increases in balances related to prior year tax positions 1,357 Increases in balances related to current year tax positions 956 Balance at December 31, 2023 $ 2,313

Organization (Details)

Organization (Details)	Jan. 20, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recapitalization exchange ratio	0.4530

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Accounts receivable	$ 6,700,000	$ 3,900,000
Accounts receivable, writeoff	0	0	$ 0
Accounts receivable, allowance for doubtful accounts	$ 0	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Other Long-Term Assets (Details)	Dec. 31, 2023
Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	2 years
Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Amortization of Website Development and Internal-use Software Costs (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Accounting Policies [Abstract]
2024	$ 6,461
2025	5,058
2026	2,568
Total	$ 14,087

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Goodwill (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) reportingUnit	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Accounting Policies [Abstract]
Number of reporting units | reportingUnit	1
Goodwill, acquired during period			$ 110,900,000
Goodwill, impairment	$ 0	$ 0	$ 0

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Intangible Assets (Details)	Dec. 31, 2023
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	1 year
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	10 years

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Impairment of Long Lived Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Impairment of long-lived assets	$ 429,000	$ 1,127,000	$ 0

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 872,000	$ 526,916	$ 271,878
Online Revenue
Disaggregation of Revenue [Line Items]
Total revenue	842,381	502,507	259,170
Wholesale Revenue
Disaggregation of Revenue [Line Items]
Total revenue	$ 29,619	$ 24,409	$ 12,708

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Stock-Based Compensation (Details)	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		4 years
Common stock issuable under the ESPP | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock, percent	85%	85%

Summary of Significant Accou_12

Summary of Significant Accounting Policies - Employee Benefit Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Percent of match	50%
Maximum annual contributions per employee, amount	$ 3
Matching contribution cost	$ 2,000	$ 1,200	$ 700

Summary of Significant Accou_13

Summary of Significant Accounting Policies - Advertising (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Customer acquisition costs	$ 390.3	$ 235.6	$ 103.5

Summary of Significant Accou_14

Summary of Significant Accounting Policies - Liquidity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Net loss	$ 23,546	$ 65,678	$ 107,659
Net cash used in operating activities	(73,483)	26,531	34,412
Accumulated deficit	368,175	344,629
Cash and cash equivalents	96,663	46,772	$ 71,784
Short-term investments	$ 124,318	$ 132,853

Recapitalization (Details)

Recapitalization (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	Jan. 20, 2021 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Jan. 19, 2021 $ / shares
Reverse Recapitalization [Line Items]
Reverse recapitalization, percentage of voting interests acquired	100%
Proceeds from issuance of common stock upon Merger | $	$ 197,700	$ 0	$ 0	$ 197,686
Reverse recapitalization, deferred transaction costs | $	$ 18,700
Recapitalization exchange ratio	0.4530
Reverse recapitalization, contingent consideration, equity (in shares) | shares	16,000,000
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger one (in dollars per share)	$ 15
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger two (in dollars per share)	17.50
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger three (in dollars per share)	$ 20
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading days	10 days
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading day period	20 days
Reverse recapitalization, contingent consideration, equity, earnout period	5 years
Chief Executive Officer
Reverse Recapitalization [Line Items]
Recapitalization exchange ratio	0.4530
Common Class A
Reverse Recapitalization [Line Items]
Class of warrant or right, number of securities called by each warrant or right (in shares) | shares	0.0028
Parent Warrant Restricted Stock Units | Hims' Option And RSU Holders
Reverse Recapitalization [Line Items]
Class of warrant or right, outstanding (in shares) | shares	35,000
Common Class A and V
Reverse Recapitalization [Line Items]
Recapitalization, contingent consideration, equity, exchange ratio	0.0443
Common Class A
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)		$ 0.0001	$ 0.0001
Common Class A | Chief Executive Officer
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)	$ 0.0001
Common Class A | Hims, Inc.
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)					$ 0.000001
Common Class A | Parent Warrants | Hims' Stockholders
Reverse Recapitalization [Line Items]
Class of warrant or right, outstanding (in shares) | shares	888,143
Common Class A | Parent Warrants | Hims' Warrant Holders
Reverse Recapitalization [Line Items]
Class of warrant or right, outstanding (in shares) | shares	3,443
Common Class V
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)		$ 0.0001	$ 0.0001
Common Class V | Chief Executive Officer
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)	$ 0.0001
Common Class V | Hims, Inc.
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)					$ 0.000001
PIPE Investment
Reverse Recapitalization [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	7,500,000
Sale of stock, price per share (in dollars per share)	$ 10
Sale of stock, consideration received on transaction | $	$ 75,000

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details)		1 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2021 USD ($)	Jul. 31, 2021 USD ($) shares	Jun. 30, 2021 USD ($) shares	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($) acquisition	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Business Acquisition [Line Items]
Number of acquisitions | acquisition					2
Goodwill						$ 110,881,000	$ 110,881,000
Honest Health Limited
Business Acquisition [Line Items]
Business combination, consideration			$ 4,800,000
Business acquisition, equity interest issued or issuable, number of shares (in shares) | shares			624,880
Business combination, consideration transferred, equity interests issued and issuable			$ 1,900,000
Business combination, consideration transferred, liabilities incurred			1,200,000
Potential earnout payable	$ 10,000,000		10,000,000
Business combination, acquisition related costs	1,900,000
Business combination, post-acquisition employee expense	700,000		700,000
Goodwill	2,739,000		2,739,000
Business acquisition, goodwill, expected tax deductible amount	$ 0		$ 0
Apostrophe
Business Acquisition [Line Items]
Business combination, consideration		$ 131,600,000
Business acquisition, equity interest issued or issuable, number of shares (in shares) | shares		8,074,935
Business combination, consideration transferred, equity interests issued and issuable		$ 50,700,000
Business combination, consideration transferred, liabilities incurred		32,700,000
Potential earnout payable		50,000,000
Business combination, acquisition related costs		5,000,000
Business combination, post-acquisition employee expense		500,000
Goodwill		108,142,000
Business acquisition, goodwill, expected tax deductible amount		0
Cash consideration		$ 48,200,000
Business combination, pro forma information, revenue of acquiree since acquisition date, actual				$ 11,000,000
Business acquisition, pro forma revenue					$ 21,000,000

Acquisitions - Assets Acquired

Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Jul. 31, 2021	Jun. 30, 2021
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Goodwill	$ 110,881	$ 110,881
Honest Health Limited
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Trade name				$ 1,470
Other intangible assets				570
Goodwill				2,739
Other net assets (liabilities)				24
Net assets acquired				$ 4,803
Apostrophe
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Trade name			$ 22,700
Other intangible assets			3,140
Goodwill			108,142
Other net assets (liabilities)			(2,346)
Net assets acquired			$ 131,636

Investments (Details)

Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Adjusted Cost	$ 124,290	$ 132,989
Unrealized Gains	43	17
Unrealized Losses	(15)	(153)
Fair Value	124,318	132,853
U.S. Treasury bills
Marketable Securities [Line Items]
Adjusted Cost	63,809
Unrealized Gains	24
Unrealized Losses	0
Fair Value	63,833
Corporate bonds
Marketable Securities [Line Items]
Adjusted Cost	39,152	99,672
Unrealized Gains	18	0
Unrealized Losses	(1)	(106)
Fair Value	39,169	99,566
Government and government agency
Marketable Securities [Line Items]
Adjusted Cost	20,624	33,317
Unrealized Gains	0	17
Unrealized Losses	(14)	(47)
Fair Value	20,610	$ 33,287
Asset-backed bonds
Marketable Securities [Line Items]
Adjusted Cost	705
Unrealized Gains	1
Unrealized Losses	0
Fair Value	$ 706

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods	$ 15,221	$ 16,477
Raw materials	7,243	5,085
Total inventory	$ 22,464	$ 21,562

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Wholesale trade receivables	$ 5,705	$ 3,231
Prepaid expenses	10,665	10,392
Other current assets	5,238	1,785
Total prepaid expenses and other current assets	$ 21,608	$ 15,408

Property, Equipment, and Soft_3

Property, Equipment, and Software, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total property, equipment, and software	$ 48,387	$ 17,440
Less: accumulated depreciation and amortization	(12,244)	(6,241)
Property, equipment, and software, net	36,143	11,199
Purchased and internal-use software and website development
Property, Plant and Equipment [Line Items]
Total property, equipment, and software	22,970	12,055
Facility equipment and other tangible property
Property, Plant and Equipment [Line Items]
Total property, equipment, and software	8,254	3,598
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property, equipment, and software	2,256	155
Assets not placed in service
Property, Plant and Equipment [Line Items]
Total property, equipment, and software	$ 14,907	$ 1,632

Property, Equipment, and Soft_4

Property, Equipment, and Software, Net - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 9,515	$ 7,474	$ 4,075
Impairment expense	400	400	$ 0
Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag			impairment expense
Property, Equipment, and Software
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 6,000	$ 3,400	$ 2,000

Intangible Assets, Net - Compon

Intangible Assets, Net - Components of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 28,973	$ 28,751
Accumulated Amortization and Impairment	(10,399)
Net Carrying Value	$ 18,574	21,841
Accumulated Amortization		$ (6,910)
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	7 years 3 months 18 days	8 years
Trade name
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 24,170	$ 24,170
Accumulated Amortization and Impairment	(6,880)
Net Carrying Value	$ 17,290	19,666
Accumulated Amortization		$ (4,504)
Trade name | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	7 years 4 months 24 days	8 years 4 months 24 days
Other
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 4,803	$ 4,581
Accumulated Amortization and Impairment	(3,519)
Net Carrying Value	$ 1,284	2,175
Accumulated Amortization		$ (2,406)
Other | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	5 years 8 months 12 days	4 years 8 months 12 days

Intangible Assets, Net (Details

Intangible Assets, Net (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense related to intangible assets	$ 3,500,000	$ 4,100,000	$ 2,100,000
Impairment of intangible assets	$ 0	$ 700,000	$ 0

Intangible Assets, Net - Amorti

Intangible Assets, Net - Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 2,800
2025	2,611
2026	2,472
2027	2,353
2028 and thereafter	8,338
Net Carrying Value	$ 18,574	$ 21,841

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accrued Liabilities and Other Liabilities [Abstract]
Marketing	$ 12,331	$ 4,990
Payroll	7,888	4,999
Professional services	5,341	643
Tax	2,009	963
Product and shipping	562	263
Other accruals	841	590
Total accrued liabilities	$ 28,972	$ 12,448

Operating Leases - Additional D

Operating Leases - Additional Detail (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease, liability, remeasurement adjustment	$ 5.7
Operating lease, right of use asset, remeasurement adjustment	5.7
Operating lease costs	2.4	$ 1.9	$ 1.8
Variable lease costs	0.4	0.3	0.3
Operating lease, payments	$ 1.9	$ 1.6	$ 1.5
Operating lease, weighted average remaining lease term	6 years 2 months 12 days
Operating lease, weighted average discount rate, percent	8.90%

Operating Leases - Lease Liabil

Operating Leases - Lease Liability (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Leases [Abstract]
2024	$ 2,114
2025	2,207
2026	2,219
2027	1,955
2028	1,696
2029 and thereafter	2,827
Gross lease payments	13,018
Less: imputed interest	(3,070)
Present value of net future minimum lease payments	$ 9,948

Variable Interest Entities (Det

Variable Interest Entities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Variable Interest Entity [Line Items]
Current assets	$ 265,053	$ 216,595
Assets	441,186	366,341
Liabilities	97,157	54,600
Net income (loss)	(23,546)	(65,678)	$ (107,659)
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Current assets	24,100	7,500
Assets	24,100	7,700
Liabilities	6,000	3,700
Net income (loss)	3,300	9,100	(3,300)
Variable Interest Entity, Primary Beneficiary | Consolidation, Eliminations | Service Agreements
Variable Interest Entity [Line Items]
Payments for services	$ 96,300	$ 64,200	$ 23,600

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out liability	$ 0	$ 2,975
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	167,666	169,630
Earn-out liability		2,975
Total liabilities		2,975
Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	107,181	25,462
Earn-out liability		0
Total liabilities		0
Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	60,485	144,168
Earn-out liability		0
Total liabilities		0
Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Earn-out liability		2,975
Total liabilities		2,975
Fair Value, Recurring | U.S. Treasury bills
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	63,833
Fair Value, Recurring | U.S. Treasury bills | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	63,833
Fair Value, Recurring | U.S. Treasury bills | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0
Fair Value, Recurring | U.S. Treasury bills | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0
Fair Value, Recurring | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	39,169	99,566
Fair Value, Recurring | Corporate bonds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Fair Value, Recurring | Corporate bonds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	39,169	99,566
Fair Value, Recurring | Corporate bonds | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Fair Value, Recurring | Asset-backed bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	706
Fair Value, Recurring | Asset-backed bonds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0
Fair Value, Recurring | Asset-backed bonds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	706
Fair Value, Recurring | Asset-backed bonds | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0
Fair Value, Recurring | Government and government agency
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	20,610	33,287
Fair Value, Recurring | Government and government agency | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Fair Value, Recurring | Government and government agency | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	20,610	33,287
Fair Value, Recurring | Government and government agency | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Fair Value, Recurring | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	42,492	24,606
Restricted cash	856	856
Fair Value, Recurring | Money market funds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	42,492	24,606
Restricted cash	856	856
Fair Value, Recurring | Money market funds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Fair Value, Recurring | Money market funds | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	$ 0	0
Fair Value, Recurring | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		11,315
Fair Value, Recurring | Government bonds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		0
Fair Value, Recurring | Government bonds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		11,315
Fair Value, Recurring | Government bonds | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		$ 0

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assumptions (Details) - Level 3 - Valuation, Income Approach - Honest Health Limited	Dec. 31, 2023
Revenue risk-adjusted discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.091
Revenue volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.500
Counterparty discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.050

Fair Value Measurements - Chang

Fair Value Measurements - Change in the Fair Value of Earn-out Liabilities (Details) - Earn-out Liability - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 2,975	$ 1,999
Change in fair value due to revaluation and service-based vesting	4,437	976
Reclassification to earn-out payable	(7,412)
Ending balance	$ 0	$ 2,975

Commitments and Contingencies -

Commitments and Contingencies - Purchase Obligations (Details) $ in Millions	Dec. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Purchase obligation	$ 7.3
Purchase obligation, payable in 2024	4.8
Purchase obligation, payable in 2025	2.4
Purchase obligation, payable in 2026	$ 0.1

Stockholders' Equity- Common St

Stockholders' Equity- Common Stock (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) commonStockClass shares	Oct. 26, 2023 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of classes of common stock | commonStockClass	2
Repurchases and retirement of common stock	$ 1,999
Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized amount		$ 50,000
Stock repurchased and retired during period (in shares) | shares	237,458
Repurchases and retirement of common stock	$ 2,000
Remaining repurchase amount	$ 48,000

Stockholders' Equity - RSU Rele

Stockholders' Equity - RSU Releases (Details) - RSUs - Common Class A - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock issued during the period (in shares)	5,201,501	2,333,695	1,810,545
Share-based payment arrangement, shares withheld for tax withholding obligation (in shares)	1,729,045	701,584	620,759

Stockholders' Equity - 2017 Sto

Stockholders' Equity - 2017 Stock Plan and 2020 Equity Incentive Plan (Details) - shares		1 Months Ended
	Jan. 01, 2023	Jan. 31, 2021	Dec. 31, 2023	Dec. 31, 2022
2020 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		21,000,000	43,612,952	33,101,677
Percentage increase in authorized shares of common stock		5%
Number of shares available for grant (in shares)			12,577,863	10,963,031
Class A common stock automatically added to the reserve (in shares)	10,421,465
Stock Plan, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized (in shares)		19,000,000
Number of shares available for grant (in shares)			0
Number of authorized shares transferred between plans (in shares)		89,810

Stockholders' Equity - 2020 Emp

Stockholders' Equity - 2020 Employee Stock Purchase Plan (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount			$ 2
Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, employee stock purchase plans (in shares)			594,885	393,528	0
Common stock issuable under the ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Automatic percentage increase of authorized shares	1%
Employee payroll deductions			$ 0.5
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			1 year 5 months 4 days
Common stock issuable under the ESPP | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		4,000,000	6,047,919	6,047,919
Number of shares benchmark (in shares)	12,000,000
Number of shares available for grant (in shares)			5,059,506	5,654,391
Purchase price of common stock, percent		85%	85%
Common stock issuable under the ESPP | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Offering period		27 months

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Options Narrative (Details)			12 Months Ended			43 Months Ended
	Feb. 24, 2022 USD ($) $ / shares shares	Jun. 17, 2020 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2023 USD ($) shares	Feb. 28, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount			$ 2,000,000			$ 2,000,000
Weighted average grant date fair value (in USD per share) | $ / shares			$ 6.09	$ 2.44	$ 6.51
Intrinsic value of exercises during period			$ 6,200,000	$ 6,300,000	$ 12,600,000
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value		$ 16,600,000
Exercisable at the end of the period (in shares) | shares							3,246,139
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount			$ 400,000			$ 400,000
Options outstanding (in shares) | shares			1,623,070			1,623,070
Chief Executive Officer | June 17, 2020 Grant One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award granted (in shares) | shares		3,246,139
Awards granted (in USD per share) | $ / shares		$ 2.43
Acquisition with shares consideration threshold (in USD per share) | $ / shares		$ 22.99
Chief Executive Officer | June 17, 2020 Grant Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award granted (in shares) | shares		1,623,070
Awards granted (in USD per share) | $ / shares		$ 2.43
Acquisition with shares consideration threshold (in USD per share) | $ / shares		$ 38.31
Chief Executive Officer | February 24, 2022 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	4 years
Award granted (in shares) | shares	2,085,640
Awards granted (in USD per share) | $ / shares	$ 5.01
Grant date fair value	$ 3,800,000
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount			$ 1,100,000			$ 1,100,000
Share based payment arrangement option share price trigger (in USD per share) | $ / shares	$ 10
Share based payment arrangement option threshold trading (in days)	$ 20
Share-based payment arrangement, option, threshold consecutive trading days (in days)	30
Chief Executive Officer | February 24, 2022 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment award, options, vested in period (in shares) | shares			0
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount			$ 15,300,000			$ 15,300,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)			10 years
Stock options | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			3 months 14 days
Stock options | Chief Executive Officer | June 17, 2020 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of vested stock options (in shares) | shares						313,257
Stock options | Chief Executive Officer | February 24, 2022 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards vesting rights, percentage	25%
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			2 years 1 month 24 days
Stock options | New Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Award vesting rights, monthly percentage			2.083%
Stock options | New Employee | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			1 year
Awards vesting rights, percentage			25%
Stock options | Current Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Award vesting rights, monthly percentage			2.083%
Stock options | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			2 years 14 days

Stockholders' Equity - Weighted

Stockholders' Equity - Weighted Average Fair Value Assumptions (Details) - Stock options	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 7 days	6 years 7 days	5 years 11 months 8 days
Expected volatility	49.90%	48%	58.60%
Risk-free interest rate	4.20%	2%	0.90%
Expected dividend yield	0%	0%	0%

Stockholders' Equity- Option Ac

Stockholders' Equity- Option Activity (Details) - Employee, excluding CEO $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares
Shares
Beginning balance (in shares) | shares	14,450
Granted (in shares) | shares	603
Exercised (in shares) | shares	(912)
Forfeited and expired (in shares) | shares	(357)
Ending balance (in shares) | shares	13,784	14,450
Exercisable at the end of the period (in shares) | shares	9,688
Weighted Average Exercise Price
Beginning balance (in USD per share) | $ / shares	$ 4.68
Granted (in USD per share) | $ / shares	11.53
Exercised (in USD per share) | $ / shares	1.74
Forfeited and expired (in USD per share) | $ / shares	6.50
Ending balance (in USD per share) | $ / shares	5.14	$ 4.68
Exercisable at the end of the period (in USD per share) | $ / shares	$ 4.55
Weighted Average Contractual Period (in Years)
Outstanding balance (in years)	7 years 1 month 20 days	7 years 11 months 23 days
Exercisable at the end of the period (in years)	6 years 8 months 4 days
Aggregate Intrinsic Value
Outstanding balance | $	$ 57,972	$ 35,771
Exercisable at the end of the period | $	$ 45,759

Stockholders' Equity - Exercise

Stockholders' Equity - Exercise Price Range of Options Outstanding and Exercisable (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Options Outstanding
Shares (in shares)	13,784	14,450
Options Exercisable
Shares (in shares)	9,688	8,389
$0.06 – 0.40
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share)	$ 0.06	$ 0.06
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share)	$ 0.40	$ 0.40
Options Outstanding
Shares (in shares)	1,422	1,830
Weighted Average Remaining Contractual Life (in Years)	4 years 2 months 23 days	5 years 2 months 15 days
Options Exercisable
Shares (in shares)	1,422	1,830
Weighted Average Remaining Contractual Life (in Years)	4 years 2 months 23 days	5 years 2 months 15 days
1.55 – 1.75
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share)	$ 1.55	$ 1.55
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share)	$ 1.75	$ 1.75
Options Outstanding
Shares (in shares)	760	959
Weighted Average Remaining Contractual Life (in Years)	5 years 4 months 13 days	6 years 5 months 4 days
Options Exercisable
Shares (in shares)	760	959
Weighted Average Remaining Contractual Life (in Years)	5 years 4 months 13 days	6 years 5 months 4 days
2.43 – 3.11
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share)	$ 2.43	$ 2.43
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share)	$ 3.11	$ 3.11
Options Outstanding
Shares (in shares)	2,751	3,037
Weighted Average Remaining Contractual Life (in Years)	6 years 5 months 4 days	7 years 6 months
Options Exercisable
Shares (in shares)	2,751	2,921
Weighted Average Remaining Contractual Life (in Years)	6 years 5 months 4 days	7 years 5 months 1 day
5.01 – 6.82
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share)	$ 5.01	$ 5.01
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share)	$ 6.82	$ 6.82
Options Outstanding
Shares (in shares)	5,913	6,190
Weighted Average Remaining Contractual Life (in Years)	8 years 2 months 4 days	9 years 2 months 15 days
Options Exercisable
Shares (in shares)	2,690	977
Weighted Average Remaining Contractual Life (in Years)	8 years 2 months 4 days	9 years 2 months 1 day
8.13 – 11.53
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share)	$ 8.13	$ 8.13
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share)	$ 11.53	$ 9.41
Options Outstanding
Shares (in shares)	2,127	1,569
Weighted Average Remaining Contractual Life (in Years)	7 years 8 months 4 days	8 years 1 month 17 days
Options Exercisable
Shares (in shares)	1,499	1,301
Weighted Average Remaining Contractual Life (in Years)	7 years 2 months 12 days	8 years 14 days
12.21 – 15.17
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share)	$ 12.21	$ 12.21
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share)	$ 15.17	$ 15.17
Options Outstanding
Shares (in shares)	811	865
Weighted Average Remaining Contractual Life (in Years)	7 years 3 months 25 days	8 years 2 months 8 days
Options Exercisable
Shares (in shares)	566	401
Weighted Average Remaining Contractual Life (in Years)	7 years 3 months 21 days	8 years 10 days

Stockholders' Equity - RSUs Nar

Stockholders' Equity - RSUs Narrative (Details) - USD ($) $ in Millions		1 Months Ended	12 Months Ended
	Mar. 01, 2023	Jan. 31, 2021	Dec. 31, 2023	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Share-based payment award, other than options, grants in period, grant date fair value			$ 12.9
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Granted (in shares)			10,198,000	45,297
Vested (in shares)			5,202,000
Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount			$ 103.8
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			2 years 10 months 28 days
RSUs | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			1 year
Awards vesting rights, percentage			25%
Earn Out Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares)			317,539
Earn Out Restricted Stock Units | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			476,308
Earn Out Restricted Stock Units | Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		4,431
Parent Warrant Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares)			6,319
Parent Warrant Restricted Stock Units | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			9,478
Parent Warrant Restricted Stock Units | Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		88
PRSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Granted (in shares)	1,115,709
Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount			$ 11.5
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			2 years 2 months 15 days
Share-based payment award, other than options, forfeited in period (in shares)			11,408
Share-based payment award, other than options, target shares percent			1
PRSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards vesting rights, percentage	0%
PRSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards vesting rights, percentage	200%

Stockholders' Equity - RSUs Act

Stockholders' Equity - RSUs Activity (Details) - RSUs - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2020
Shares
Beginning balance (in shares)	11,601,000
Granted (in shares)	10,198,000	45,297
Vested (in shares)	(5,202,000)
Forfeited and expired (in shares)	(2,114,000)
Ending balance (in shares)	14,483,000
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 6.40
Granted (in dollars per share)	9.64
Vested (in dollars per share)	7.54
Forfeited and expired (in dollars per share)	7.40
Ending balance (in dollars per share)	$ 8.08

Stockholders' Equity - Vendor W

Stockholders' Equity - Vendor Warrants Narrative (Details) - Vendor Warrants $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock outstanding and exercisable (in shares)	462,335
Exercisable at the end of period (in shares)	462,335
Outstanding common stock warrants (in shares)	462,335
Exercisable and outstanding, weighted average exercise price (in usd per share) | $ / shares	$ 1.75
Exercisable and outstanding, weighted average remaining contractual terms	7 years 3 days
Exercisable and outstanding, aggregate intrinsic value | $	$ 3.3
Earn-Out Consideration
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number securities called by warrants or rights (in shares)	45,225
Pre Merger Debt Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock outstanding and exercisable (in shares)	98,723
Exercisable at the end of period (in shares)	98,723
Outstanding common stock warrants (in shares)	98,723
Exercisable and outstanding, weighted average exercise price (in usd per share) | $ / shares	$ 6.96
Exercisable and outstanding, weighted average remaining contractual terms	6 years 8 months 15 days
Exercisable and outstanding, aggregate intrinsic value | $	$ 0.2

Stockholders' Equity - Stock Su

Stockholders' Equity - Stock Subject to Vesting and Earn-out Share Liability (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Jul. 31, 2021	Jun. 30, 2021	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Restricted Stock | Honest Health Limited
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, amount			$ 2
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			1 year 5 months 12 days
Restricted Stock | Apostrophe
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, amount			$ 3.7
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			6 months
Restricted Stock | Employee | Honest Health Limited
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		4 years
Restricted Stock | Employee | Honest Health Limited | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		1 year
Awards vesting rights, percentage		25%
Restricted Stock | Employee | Honest Health Limited | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		447,553
Aggregate grant date fair value		$ 5.5
Restricted Stock | Employee | Apostrophe
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Restricted Stock | Employee | Apostrophe | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	6 months
Awards vesting rights, percentage	17%
Restricted Stock | Employee | Apostrophe | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	2,332,557
Aggregate grant date fair value	$ 24.2

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock-Based Compensation Expense for Employees and Nonemployees (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 66,080	$ 42,817	$ 67,211
Share-based payment arrangement, amount capitalized	1,700	600	700
Marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	5,477	4,648	9,664
Operations and support
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	6,815	2,684	2,735
Technology and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	7,126	4,327	4,481
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 46,662	$ 31,158	$ 50,331

Related-Party Transactions (Det

Related-Party Transactions (Details) - Affiliated Entity - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Terminal, Inc.
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party	$ 4.6	$ 3.6	$ 3.5
Vouched
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party	$ 2.1	$ 1	$ 0.7

Basic and Diluted Net Loss pe_3

Basic and Diluted Net Loss per Share - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Dividends, common stock	$ 0	$ 0	$ 0

Basic and Diluted Net Loss pe_4

Basic and Diluted Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net loss attributable to common stockholders	$ (23,546)	$ (65,678)	$ (107,659)
Denominator:
Weighted average shares outstanding, basic (in shares)	209,344,712	204,516,120	186,781,537
Weighted average shares outstanding, diluted (in shares)	209,344,712	204,516,120	186,781,537
Basic net loss per share (in USD per share)	$ (0.11)	$ (0.32)	$ (0.58)
Diluted net loss per share (in USD per share)	$ (0.11)	$ (0.32)	$ (0.58)
Common Class A
Numerator:
Net loss attributable to common stockholders	$ (22,604)	$ (62,988)	$ (103,082)
Denominator:
Weighted average shares outstanding, basic (in shares)	200,967,089	196,138,497	178,840,009
Weighted average shares outstanding, diluted (in shares)	200,967,089	196,138,497	178,840,009
Basic net loss per share (in USD per share)	$ (0.11)	$ (0.32)	$ (0.58)
Diluted net loss per share (in USD per share)	$ (0.11)	$ (0.32)	$ (0.58)
Common Class V
Numerator:
Net loss attributable to common stockholders	$ (942)	$ (2,690)
Denominator:
Weighted average shares outstanding, basic (in shares)	8,377,623	8,377,623
Weighted average shares outstanding, diluted (in shares)	8,377,623	8,377,623
Basic net loss per share (in USD per share)	$ (0.11)	$ (0.32)
Diluted net loss per share (in USD per share)	$ (0.11)	$ (0.32)
Common Class F
Numerator:
Net loss attributable to common stockholders			$ (4,577)
Denominator:
Weighted average shares outstanding, basic (in shares)			7,941,528
Weighted average shares outstanding, diluted (in shares)			7,941,528
Basic net loss per share (in USD per share)			$ (0.58)
Diluted net loss per share (in USD per share)			$ (0.58)

Basic and Diluted Net Loss pe_5

Basic and Diluted Net Loss per Share - Schedule of Excluded Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	21,278,043	20,470,391	16,345,661
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	15,220,986	8,778,890	4,081,026
Common stock issued subject to vesting
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,090,181	2,027,852	1,419,613
PRSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	928,642	0	0
Warrants | Common Class A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	561,058	561,058	4,778,003
Common stock issuable under the ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	404,648	603,603	136,538
Common stock issued for early exercise of stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	70,257	196,431
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	0	4,858,176
Common stock issued for exercise of stock options subject to nonrecourse promissory notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	0	874,312

Income Taxes - Loss Before Prov

Income Taxes - Loss Before Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Domestic	$ (16,749)	$ (62,539)	$ (109,393)
Foreign	(4,822)	(3,170)	(1,402)
Loss before income taxes	$ (21,571)	$ (65,709)	$ (110,795)

Income Taxes - Components Attri

Income Taxes - Components Attributable to the Provision for Income Taxes (Details) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current:
Federal	$ 532	$ 0	$ 0
State	1,456	563	252
Total current provision	1,988	563	252
Deferred:
Federal	12	(339)	(2,280)
State	(25)	(110)	(966)
Foreign	0	(145)	(142)
Total deferred benefit	(13)	(594)	(3,388)
Total provision (benefit) for income taxes	$ 1,975	$ (31)	$ (3,136)

Income Taxes - Effective Income

Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Tax benefit at federal statutory rate	$ (4,530)	$ (13,799)	$ (23,267)
State taxes, net of federal benefits	1,636	(609)	(3,498)
Transaction costs	0	(731)	369
Stock-based compensation	1,747	3,897	2,018
Warrants and earn-outs	226	(15)	(1,710)
Non-deductible officers' compensation	6,386	2,881	8,352
Change in valuation allowance	1,330	7,794	15,971
Research and development credits	(5,398)	0	0
Non-deductible expenses	714	613	0
Other, net	(136)	(62)	(1,371)
Total provision (benefit) for income taxes	$ 1,975	$ (31)	$ (3,136)

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating loss carryforwards	$ 53,309	$ 67,214
Research and other credits	3,779	0
Capitalized research and development	15,106	0
Accrued expenses and reserves	2,164	1,952
Stock-based compensation	3,572	4,079
Inventory	1,890	2,338
Other intangible assets	350	487
Deferred revenue	124	17
Operating lease liabilities	2,615	1,382
Other deferred tax assets	87	553
Total gross deferred tax assets	82,996	78,022
Less valuation allowance	(70,506)	(69,357)
Total deferred tax assets	12,490	8,665
Deferred tax liabilities:
Other intangible assets	(4,777)	(5,623)
Fixed assets	(1,532)	(1,722)
Prepaid expenses	(1,825)	0
Operating lease right-of-use assets	(2,519)	(1,285)
Other deferred tax liabilities	(1,859)	(70)
Total deferred tax liabilities	(12,512)	(8,700)
Net deferred tax liabilities	$ (22)	$ (35)

Income Taxes - Additional Detai

Income Taxes - Additional Details (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Contingency [Line Items]
Valuation allowance, deferred tax asset, increase (decrease), amount	$ 1,100,000	$ 8,000,000
Operating loss carryforwards, domestic	186,100,000
Operating loss carryforwards, state	154,800,000
Operating loss carryforwards, foreign	10,800,000
Tax carryforwards	6,100,000
Unrecognized tax benefits	2,313,000	0	$ 0
Unrecognized interest or penalties	0	$ 0	$ 0
Federal
Income Tax Contingency [Line Items]
Operating loss carryforwards, not subject to expiration	186,100,000
State
Income Tax Contingency [Line Items]
Operating loss carryforwards, not subject to expiration	17,500,000
Foreign
Income Tax Contingency [Line Items]
Operating loss carryforwards, not subject to expiration	$ 10,800,000

Income Tax - Unrecognized Tax B

Income Tax - Unrecognized Tax Benefits (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 0
Increases in balances related to prior year tax positions	1,357,000
Increases in balances related to current year tax positions	956,000
Ending balance	$ 2,313,000

Subsequent Events (Details)

Subsequent Events (Details) $ in Thousands	1 Months Ended
	Feb. 26, 2024 USD ($) ft²	Dec. 31, 2023 USD ($)
Subsequent Event [Line Items]
Minimum lease payments		$ 13,018
Gilbert, Arizona | Subsequent Event
Subsequent Event [Line Items]
Operating lease, term of contract	28 months
Area of real estate property | ft²	29,467
Minimum lease payments	$ 1,000
Lessee, operating lease, rent abatement period	2 months
Rent expense, annual escalation, percent	4%
Operating lease, renewal term	1 year